US drug shortages hit a record 323 in the first quarter of 2024, steadily increasing since 2021.

All drug classes are vulnerable to shortages, particularly sterile injectables, cancer chemotherapy, and emergency drugs.

The five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, intravenous fluids, and 32 chemotherapy drugs.

Over half a million patients, mostly elderly, have been affected by treatment shortages lasting over two years.

Manufacturing and quality problems are often the root cause of drug shortages, rather than just growing demand.

The American Society of Health System Pharmacists opposes financial sanctions on under-resourced hospitals for non-compliance with shortage management recommendations.

Large health systems often exacerbate shortages by placing large orders when they are anticipated.

Lack of transparency in the supply chain hinders the ability to respond to shortages.

Requiring manufacturers to disclose suppliers, like in New Zealand, could help address drug shortages.

Most hospital pharmacists are reporting a critical shortage of chemotherapy drugs, forcing hospitals to delay, cancel or ration care.

99% of hospital pharmacists are reporting drug shortages, with 309 affected medications, nearing the 2014 record high of 320.

Hospitals are substituting drugs and changing treatment plans due to key drug shortages, putting patients at risk.

Cancer drug shortages, including cisplatin and carboplatin, are affecting treatment for various cancers, with over a dozen drugs in shortage.

Medications for heart conditions, emergency syringes, and ICU drugs are in short supply, say some pharmacists.

Pharmacists are managing shortages by offering alternatives, adjusting purchases, and rationing, with about two-thirds finding them 'moderately impactful'.

France's drug shortages rose from 2,160 in 2021 to 3,761 in 2022 and 4,925 in 2023.

A 2024 survey found 44% of people in France had faced a drug shortage, prompting calls for pharmaceutical transparency.

French pharmacy unions plan to strike over drug shortages.

Health organisations recommend transparency, stock monitoring, and equal access to care regarding drug shortages.

The European Commission has announced pharmaceutical industry reforms amid criticism.

The European Parliament has adopted a position on pharmaceutical reform, including innovation incentives and antibiotic overuse limits.

Non-profit organisations have called for the EU to require pharmaceutical companies to hold safety stocks of medicine.

The drug shortage is not due to a lack of raw materials.

Pharmacists pay 33% out of pocket for certain drugs, like magnesium oxide, which exceed the health insurance price.

Authorities' lack of planning has contributed to the drug shortage since 2015.

The Ministry of Health and Welfare announced 15 scarce drugs, but offered no solution.

Jordanian hospitals face a medicine shortage due to a 300 million dinar debt to pharmaceutical companies.

Delays in payment to pharmaceutical companies have led to a medicine shortage, with unpaid debts from 2020 to August 2023.

Inadequate data on patient numbers and hospital needs has hindered sub-budget preparation for hospitals.

Poor coordination between hospitals, the Ministry of Health, and pharmaceutical companies has complicated medicine supply and distribution.

Funding issues have contributed to medication shortages.

Medication shortages can lead to threats to patient safety, economic implications, and increased stress on healthcare workers and patients.

Preparing budgets, improving coordination, and implementing reforms can help overcome medication shortages.

A shortage of essential medications is a significant issue in hospitals and pharmacies.

High demand, especially during flu season, contributes to the shortage.

Essential medications are on backorder, making restocking difficult for pharmacies.

COVID-19 pandemic-related supply chain issues may be contributing to the medication shortage.

Fewer manufacturers producing certain medications contribute to the shortage.

The shortage also affects ADHD and blood pressure medications.

Using medications like antibiotics only when necessary helps preserve them for those who truly need them.

The Ukraine-Russia conflict caused a 30-year high in drug shortages due to supply chain disruptions and raw material scarcity.

The FDA's limited release of certain raw materials, like ephedrine, causes a shortage of related drugs.

Price cuts have led pharmaceutical companies to withdraw from the health insurance market, causing a drug shortage.

The Red Sea conflict has increased freight costs by 180%, exacerbating the medicine shortage.

The US had a record 323 drug shortages in early 2024, surpassing the 2014 high of 320.

The shortage affected various drug categories, including diabetes, allergy, antibiotic, chemotherapy, and emergency medications.

Sterile injectable drugs, including cancer chemotherapy, were among the most worrying shortages.

The shortage of chemotherapy drugs has devastated patients, forcing hospitals to ration medications.

A nationwide shortage of ADHD drugs persists.

Demand for drugs like Mounjaro has led to shortages due to manufacturers' struggles to keep up with production.

Fragmentation of the US drug supply chain contributes to drug shortages.

The White House proposes spending $3.26 billion to $5.11 billion over the next decade to address the nation's drug shortage.

U.S. researchers and policymakers believe a complete solution to the drug shortage may require changes to the U.S. pharmaceutical industry's business model.

Policymakers recommend giving the FDA more power to access drug shortage information.

Hospitals have struggled with medication shortages, rising costs, and falling revenues between 2021 and 2024.

The COVID-19 pandemic has worsened healthcare system issues, including staffing shortages and rising medication and PPE costs.

Hospitals face high costs for temporary staffing, with contract nurses often costing two to three times more than staff nurses.

Staffing shortages, including a nurse shortage, have increased care costs and pressured hospitals to find creative solutions.

Governments must continue to support hospitals as they face various challenges.

Ireland had a paracetamol shortage in 2023 due to a surge in Covid-19 and flu cases.

The shortage affected some prescription paracetamol products, but alternatives were available.

Medicine shortages have increased worldwide over the past decade due to raw material shortages, manufacturing difficulties, and industry consolidations.

Managing medicine shortages requires a multi-faceted response to ensure patient safety.

Only about 400 treatments exist for over 7,000 known rare diseases, causing a global medication shortage.

China has approved 89 drugs for 45 rare diseases, covering 53% of globally treatable rare diseases.

The cost of medical treatment for rare diseases can be very high, reaching tens of millions of yuan annually.

Many rare disease drugs are not covered by basic medical insurance, making them unaffordable for patients.

China has set up mechanisms, including funds and insurance, to help rare disease patients access expensive drugs.

The IV paracetamol shortage is expected to last until at least November due to manufacturing capacity constraints.

Drug shortages have become a global problem, worsened by the Covid pandemic, the Ukraine war, and economic crises.

The Covid pandemic has worsened the global medication shortage.

The war in Ukraine has worsened the global medication shortage.

The energy crisis has worsened the global medication shortage.

Inflation has worsened the global medication shortage.

Brexit has worsened Great Britain's medication shortage problem.

EU drug imports, which make up two-thirds of the NHS's supply, are at a record low since Brexit.

The global medication shortage has persisted from 2021 to 2024 with no end in sight.

The FDA reported 111 US drug shortages as of December 2021.

The FDA attributed the shortages to production and quality problems.

About 80% of active pharmaceutical ingredient manufacturers, mostly overseas, provide the FDA with drug shortage information.

The FDA will work with manufacturers to address the shortage.

US medicine shortages rose 30% in 2022 from 2021.

Medicine shortages typically last 18 months, but can persist for up to 15 years.

Drugs like antibiotics and anesthetics are in short supply.

Most medical products are made abroad, contributing to the shortage.

Economic factors and supply chain issues cause the medication shortage.

Production capacity in countries like India and China creates vulnerability to natural disasters and political unrest.

A shortage of critical drugs threatens U.S. national security.

US drug shortages hit a record 323 in the first quarter of 2024, steadily increasing since 2021.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
An Unexpected Catastrophe in the World ’ s Largest Country: The Complete Story of U.S. Drug Shortages
The deficit is at a record level.
According to data from the American Society of Health System Pharmacists and the University of Utah Drug Information Service, organizations began tracking drug shortages for the first time in 2001. Steady since 2021 – now reaching a record high of 323 drugs in the first three months of 2024.
Paul Abramowitz, CEO of the American Society of Health System Pharmacists, wrote in a blog post on Thursday: “It ’ s been a long time to end drug shortages, ” and wrote:“ All drug classes are vulnerable to shortages, some of the most worrisome shortages include sterile injectable generic drugs, including cancer chemotherapy drugs and emergency drugs stored in hospital vans and procedural areas. It is dangerous for doctors and patients. ”
In addition to the 32 chemotherapy drugs that are deficient, the five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, and intravenous fluids. [1] The Drug Deficiency Database maintained by the American Society of Health System Pharmacists and the University of Utah is based on voluntary reports from practitioners, patients, and others that have been confirmed by manufacturers. The U.S. drug is in short supply, because it captures broader effects on service providers and patients.
The crisis has lasted a year and a half.
More than half of the treatment shortages have lasted for more than two years, according to an analysis by health consultancy IQVIA, and the average shortage affects at least half a million patients, many of them elderly, according to the US Office of Health and Human Services under the Assistant Secretary for Planning and Evaluation, which shared its analysis with Congress in May.
Growing demand can play a role in drug shortages, as with the recent shortage of weight-loss drugs, but often manufacturing and quality problems, such as supply chain gaps and downtime, are the root cause. And varied.
But the American Society of Health System Pharmacists has “serious concerns ” about parts of this proposal, especially financial sanctions imposed on hospitals that lack the resources to comply with the recommendations, Abramowitz wrote:“ We all know that managing shortages is not enough and is not a sustainable solution to the worsening crisis, and there is still a lot of work to be done at the federal level to fix the root causes of drug shortages. ”
Why Shortage Occurs
Shortages can be caused by high demand, as with the recent shortage of weight-loss drugs, but this is not usually the main problem.
The FDA also blames manufacturing and quality problems, supply chain gaps, and downtime, and Dr. Emily Tucker, a drug shortage expert and an assistant professor of industrial engineering at Clemson University, says that when there is an indication of shortages, large health systems often also proactively place large orders, adding to the system ’ s stress.
“I don ’ t blame anyone.
“When I talk to all the stakeholders – whether it ’ s wholesalers, manufacturers, or the government – everyone wants this problem to end, ” she said.
Lack of transparency
Dr. Julie Grallo, chief medical officer and executive vice president of the American Society of Clinical Oncology, told the House Committee earlier that the shortage puts providers in a terrible position: “The drug shortage crisis is forcing providers to make impossible choices, and it is also hindering the development of new drugs. Health drugs are purchased only on a price basis, and manufacturers do not have to disclose the source of their acquisition of the ingredients.
The shortage of this generic chemical drug came due to the closure of one factory in India that manufactures the active ingredient after a surprise FDA inspection found “significant quality issues, ” says Jarallo:“ We didn ’ t know, and there was no transparency regarding the company ’ s supply of the majority of active pharmaceutical ingredients to all manufacturers across the board.
Knowing this in advance, we could have responded much faster, ” Dr. Steven Schundlemeyer, director of the PRIME Institute of the University of Minnesota School of Pharmacy, which focuses on economic and management issues, told the committee that as with defense contractors in the United States, New Zealand requires manufacturers to disclose their suppliers, and that information is required.
Easily accessible in the database.
Related Topics

All drug classes are vulnerable to shortages, particularly sterile injectables, cancer chemotherapy, and emergency drugs.

The five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, intravenous fluids, and 32 chemotherapy drugs.

Over half a million patients, mostly elderly, have been affected by treatment shortages lasting over two years.

Manufacturing and quality problems are often the root cause of drug shortages, rather than just growing demand.

The American Society of Health System Pharmacists opposes financial sanctions on under-resourced hospitals for non-compliance with shortage management recommendations.

Large health systems often exacerbate shortages by placing large orders when they are anticipated.

Lack of transparency in the supply chain hinders the ability to respond to shortages.

Requiring manufacturers to disclose suppliers, like in New Zealand, could help address drug shortages.

Most hospital pharmacists are reporting a critical shortage of chemotherapy drugs, forcing hospitals to delay, cancel or ration care.

Title:

Content: As drug shortage list grows, many hospitals face tough decisions on rationing care

More than half of hospital pharmacists are reporting a critical shortage of chemotherapy drugs and nearly all are reporting overall medicine supply gaps as prescription drug shortages near an all time high, according to a new survey.

Hospital pharmacists said drug shortages have forced 1 in 3 health systems to delay, cancel or ration care or switch to alternate drugs to continue to treat patients. And 99% are reporting some drug supply shortages, an American Society of Health-System Pharmacists survey of more than 1,000 pharmacists released Thursday found.

The organization reported shortages of 309 drugs, near the all-time high of 320 shortages in 2014. The scarcity of key drugs is prompting hospitals to find or substitute drugs and change treatment plans as needed.

“In some cases, there are no alternatives to the affected drugs, which puts patients at risk," ASHP Chief Executive Officer Paul W. Abramowitz said in a statement. "This issue requires quick action from Congress to address the underlying causes of shortages and ensure patients have the medications they need.”

Cancer drug shortages

In June, the Food and Drug Administration said it will temporarily allow overseas drug manufacturers to import some chemotherapy drugs.

The FDA allowed Qilu Pharmaceutical, a drug manufacturer in China, to import the injectable chemotherapy drug cisplatin in 50-milligram vials. Toronto pharmaceutical company Apotex Corp. will distribute the medication in the United States.

More than a dozen cancer drugs have been in shortage in recent months, including cisplatin and carboplatin, used to treat lung, breast, prostate and gynecologic cancers. The National Cancer Institute said cisplatin and similar drugs are prescribed for 10% to 20% of all cancer patients.

In June, the National Comprehensive Cancer Network released a survey of 27 academic cancer centers that found 93% reported shortages of carboplatin and 70% faced shortages of cisplatin.

When cancer hospitals face such shortages, they attempt to make sure there's enough medication for patients to finish the course of treatment, said Mike Ganio, ASHP's senior director of pharmacy practice and quality.

Cancer hospitals facing such shortages might change medications for new patients starting on chemotherapy, said Ganio, a former pharmacy manager at an academic cancer center.

"You try to keep that patient on the same regimen as much as you can, unless they're failing it for some reason, and then you would switch," Ganio said.

Steroids, hormonal drugs also in short supply

More than 1 in 5 hospital pharmacists also reported shortages for steroids, hormonal drugs and oral liquids such as lidocaine, ibuprofen and amoxicillin.

A smaller number of pharmacists said heart medications, emergency prefilled syringes and drugs used for intensive care unit patients were in short supply. Others reported shortages of attention deficit hyperactivity disorder medicines, antimicrobial drugs and injectable opioids.

In all, about two-thirds of pharmacists said the shortages were "moderately impactful," which means they are managing shortages but patients are affected.

Pharmacists are managing the shortages by offering therapeutic alternatives, buying different vial sizes or concentrations and rationing medicines.

This article originally appeared on USA TODAY: Survey: Drug shortages are widespread, hospitals ration care

99% of hospital pharmacists are reporting drug shortages, with 309 affected medications, nearing the 2014 record high of 320.

Hospitals are substituting drugs and changing treatment plans due to key drug shortages, putting patients at risk.

Cancer drug shortages, including cisplatin and carboplatin, are affecting treatment for various cancers, with over a dozen drugs in shortage.

Medications for heart conditions, emergency syringes, and ICU drugs are in short supply, say some pharmacists.

Pharmacists are managing shortages by offering alternatives, adjusting purchases, and rationing, with about two-thirds finding them 'moderately impactful'.

France's drug shortages rose from 2,160 in 2021 to 3,761 in 2022 and 4,925 in 2023.

Title:

Content: French health groups put forward proposals to limit the damage of worsening drug shortages

Medicines such as cough syrup, lozenges and ointment are seen on a table in an apartment in Berlin, Tuesday, December 20, 2022. Copyright Stephanie Pilick/dpa via AP
Copyright Stephanie Pilick/dpa via AP
By Lauren Chadwick
Share this articleComments
Share this article

Pharmaceutical companies’ lack of transparency leads to rising drug prices and less control over public resources, the group of health organisations say.

ADVERTISEMENT

A group of French organisations have called for more transparency from pharmaceutical companies as drug shortages increase.

In a joint report, 14 civil society organisations outlined their recommendations to solve a “situation that has only worsened” since 2018.

The French medicines regulator signalled 4,925 drug shortages in 2023, compared to 3,761 in 2022 and 2,160 in 2021.

A 2024 survey from France Assos Santé, which represents patients, found that 44 per cent of people in France said they had faced a drug shortage this year.

One of the pharmacy unions in France has even planned a strike at the end of the month over drug shortages and what they say is worsening access to care.

Each health organisation contributed an article with recommendations for dealing with the drug shortages.

The League Against Cancer urged complete transparency on drug shortages and potential substitutions for health professionals.

They also called for monitoring of medicine stocks and their location in the country to guarantee equal access.

The organisation found in a survey published in February that 78 per cent of health professionals in oncology had been faced with a drug shortage.

Drug shortages or delays have led to anxiety among cancer patients, lost time, and worsening symptoms, the organisation said.

France Assos Santé, meanwhile, wrote that an urgent response should not be to support “the industrial sector which bears serious responsibilities” for abandoning the production of less profitable drugs, relocating drug production, and keeping insufficient medicine stocks.

They would like any cost increases justified by production costs or the risk of withdrawing a drug from the market due to it being unprofitable. They called for cost evaluations to be made public.

Their concerns also range from the use of public money to bring drug production to Europe to new government plans to prevent shortages.

Some changes at the EU level criticised

Last year, the European Commission announced several measures to reform the pharmaceutical industry and address critical drug shortages.

The European Parliament went on to adopt a position on pharmaceutical reform last month, that included “incentives for innovation” and an effort to limit overuse of antibiotics.

The non-profit organisation Prescrire, which focuses on information about medicine, wrote in a chapter they contributed to the report that while some of the European Commission’s measures were welcome, others were concerning.

One of the many measures they rejected included the Commission’s proposal to reduce the number of days of scientific evaluation of drugs from 210 to 180, which they said was necessary time rather than an “administrative obstacle”.

While the NGO welcomed some measures such as government drug shortage prevention plans, it said the Commission should allow EU states to require pharmaceutical companies to have safety stocks of medicine and sanction those that do not respect them.

ADVERTISEMENT

French consumer organisation UFC-Que Choisir and the European Consumer Organisation (BEUC) said that they had hoped MEPs would shorten the length of time for “data protection” to allow generic medicines to be marketed more quickly.

Instead, MEPs approved shortening the period to 7.5 years, “which is almost the same duration as the current 8 years [yet] within the framework of the text adopted by Parliament, companies can gain additional months of protection under certain conditions to reach a total of 8.5 years,” UFC-Que Choisir said.

Share this articleComments

You might also like

A 2024 survey found 44% of people in France had faced a drug shortage, prompting calls for pharmaceutical transparency.

French pharmacy unions plan to strike over drug shortages.

Health organisations recommend transparency, stock monitoring, and equal access to care regarding drug shortages.

The European Commission has announced pharmaceutical industry reforms amid criticism.

The European Parliament has adopted a position on pharmaceutical reform, including innovation incentives and antibiotic overuse limits.

Non-profit organisations have called for the EU to require pharmaceutical companies to hold safety stocks of medicine.

The drug shortage is not due to a lack of raw materials.

Title:

Content: The lack of drugs caused public resentment, the Ministry of Health and Welfare yesterday (27th) held a press conference to announce the 15 most scarce drugs in the country, including antibiotics, fever, diarrhea, etc., and the Director of Health Insurance Shi Chongliang also stressed that the price of drugs will not be adjusted this year. It costs 33% on a single charge, because the cost of the project is much higher than the health insurance price.
From 2015 to 2023, the problem that you want to rely on a press conference to solve? It only shows that the authorities have no plans at all, and the pharmacists have to continue to work hard on their own.
"I sometimes feel that pharmacists put too much of their social responsibility, but at the same time, I am glad that these pharmacists are willing to bear heavy burdens to keep our years quiet." Facebook fan "Sanbao · pharmacist · God Uncle" pointed out in a Facebook post today (28), why is there a shortage of drugs? The number of drugs in the department is not enough to supply the prescription prescribed by the hospital clinic. "
But it is not because of raw materials, because of capacity, or because of the supply chain, which depends on these people who have the resources to trace the source.
Sanbao pharmacist stressed, "before 2020 you say lack of medicine, the Food and Drug Department will tell you that you do not check the word may be fined 3 million!" At that time, he and a friend and a fan group have been reminding the Association of pharmacists to pay attention to lack of medicine, do not hold annual garden parade to whitewash the peace, of course, this argument at that time few people accept, after all, the lottery is what the public like.
And the problem that started in 2015 and continued to swing into 2023, now that I want a press conference to solve? This is as difficult as Xiao Xu getting married before the end of the year and performing a double transformation at the wedding.
Three Treasures Pharmacist bluntly said that yesterday's press conference only highlighted that the authorities had no planning at all, and even the original three-tong policy was an entire situation.
"In my opinion, pharmacists have to continue to work on their own!" To put it mildly, the magnesium oxide produced by the government project (soft stool, acid preparation, 110 years of health insurance use of 250 million pills), pharmacists will pay 33% for each order, because the cost of the project is much higher than the health insurance price.
The pharmacist who is serious about finding drugs to help patients is on the road of the Chao Pharma-Buddha. "There are three children in my family, and it is really impossible to be like the chairman of the board of directors who do not care about remuneration."
# Cai Government # Lack of Drugs # Food and Drug Administration # Ministry of Health and Welfare # Scrap

Pharmacists pay 33% out of pocket for certain drugs, like magnesium oxide, which exceed the health insurance price.

Title:

Content: The lack of drugs caused public resentment, the Ministry of Health and Welfare yesterday (27th) held a press conference to announce the 15 most scarce drugs in the country, including antibiotics, fever, diarrhea, etc., and the Director of Health Insurance Shi Chongliang also stressed that the price of drugs will not be adjusted this year. It costs 33% on a single charge, because the cost of the project is much higher than the health insurance price.
From 2015 to 2023, the problem that you want to rely on a press conference to solve? It only shows that the authorities have no plans at all, and the pharmacists have to continue to work hard on their own.
"I sometimes feel that pharmacists put too much of their social responsibility, but at the same time, I am glad that these pharmacists are willing to bear heavy burdens to keep our years quiet." Facebook fan "Sanbao · pharmacist · God Uncle" pointed out in a Facebook post today (28), why is there a shortage of drugs? The number of drugs in the department is not enough to supply the prescription prescribed by the hospital clinic. "
But it is not because of raw materials, because of capacity, or because of the supply chain, which depends on these people who have the resources to trace the source.
Sanbao pharmacist stressed, "before 2020 you say lack of medicine, the Food and Drug Department will tell you that you do not check the word may be fined 3 million!" At that time, he and a friend and a fan group have been reminding the Association of pharmacists to pay attention to lack of medicine, do not hold annual garden parade to whitewash the peace, of course, this argument at that time few people accept, after all, the lottery is what the public like.
And the problem that started in 2015 and continued to swing into 2023, now that I want a press conference to solve? This is as difficult as Xiao Xu getting married before the end of the year and performing a double transformation at the wedding.
Three Treasures Pharmacist bluntly said that yesterday's press conference only highlighted that the authorities had no planning at all, and even the original three-tong policy was an entire situation.
"In my opinion, pharmacists have to continue to work on their own!" To put it mildly, the magnesium oxide produced by the government project (soft stool, acid preparation, 110 years of health insurance use of 250 million pills), pharmacists will pay 33% for each order, because the cost of the project is much higher than the health insurance price.
The pharmacist who is serious about finding drugs to help patients is on the road of the Chao Pharma-Buddha. "There are three children in my family, and it is really impossible to be like the chairman of the board of directors who do not care about remuneration."
# Cai Government # Lack of Drugs # Food and Drug Administration # Ministry of Health and Welfare # Scrap

Authorities' lack of planning has contributed to the drug shortage since 2015.

Title:

Content: The lack of drugs caused public resentment, the Ministry of Health and Welfare yesterday (27th) held a press conference to announce the 15 most scarce drugs in the country, including antibiotics, fever, diarrhea, etc., and the Director of Health Insurance Shi Chongliang also stressed that the price of drugs will not be adjusted this year. It costs 33% on a single charge, because the cost of the project is much higher than the health insurance price.
From 2015 to 2023, the problem that you want to rely on a press conference to solve? It only shows that the authorities have no plans at all, and the pharmacists have to continue to work hard on their own.
"I sometimes feel that pharmacists put too much of their social responsibility, but at the same time, I am glad that these pharmacists are willing to bear heavy burdens to keep our years quiet." Facebook fan "Sanbao · pharmacist · God Uncle" pointed out in a Facebook post today (28), why is there a shortage of drugs? The number of drugs in the department is not enough to supply the prescription prescribed by the hospital clinic. "
But it is not because of raw materials, because of capacity, or because of the supply chain, which depends on these people who have the resources to trace the source.
Sanbao pharmacist stressed, "before 2020 you say lack of medicine, the Food and Drug Department will tell you that you do not check the word may be fined 3 million!" At that time, he and a friend and a fan group have been reminding the Association of pharmacists to pay attention to lack of medicine, do not hold annual garden parade to whitewash the peace, of course, this argument at that time few people accept, after all, the lottery is what the public like.
And the problem that started in 2015 and continued to swing into 2023, now that I want a press conference to solve? This is as difficult as Xiao Xu getting married before the end of the year and performing a double transformation at the wedding.
Three Treasures Pharmacist bluntly said that yesterday's press conference only highlighted that the authorities had no planning at all, and even the original three-tong policy was an entire situation.
"In my opinion, pharmacists have to continue to work on their own!" To put it mildly, the magnesium oxide produced by the government project (soft stool, acid preparation, 110 years of health insurance use of 250 million pills), pharmacists will pay 33% for each order, because the cost of the project is much higher than the health insurance price.
The pharmacist who is serious about finding drugs to help patients is on the road of the Chao Pharma-Buddha. "There are three children in my family, and it is really impossible to be like the chairman of the board of directors who do not care about remuneration."
# Cai Government # Lack of Drugs # Food and Drug Administration # Ministry of Health and Welfare # Scrap

The Ministry of Health and Welfare announced 15 scarce drugs, but offered no solution.

Title:

Content: The lack of drugs caused public resentment, the Ministry of Health and Welfare yesterday (27th) held a press conference to announce the 15 most scarce drugs in the country, including antibiotics, fever, diarrhea, etc., and the Director of Health Insurance Shi Chongliang also stressed that the price of drugs will not be adjusted this year. It costs 33% on a single charge, because the cost of the project is much higher than the health insurance price.
From 2015 to 2023, the problem that you want to rely on a press conference to solve? It only shows that the authorities have no plans at all, and the pharmacists have to continue to work hard on their own.
"I sometimes feel that pharmacists put too much of their social responsibility, but at the same time, I am glad that these pharmacists are willing to bear heavy burdens to keep our years quiet." Facebook fan "Sanbao · pharmacist · God Uncle" pointed out in a Facebook post today (28), why is there a shortage of drugs? The number of drugs in the department is not enough to supply the prescription prescribed by the hospital clinic. "
But it is not because of raw materials, because of capacity, or because of the supply chain, which depends on these people who have the resources to trace the source.
Sanbao pharmacist stressed, "before 2020 you say lack of medicine, the Food and Drug Department will tell you that you do not check the word may be fined 3 million!" At that time, he and a friend and a fan group have been reminding the Association of pharmacists to pay attention to lack of medicine, do not hold annual garden parade to whitewash the peace, of course, this argument at that time few people accept, after all, the lottery is what the public like.
And the problem that started in 2015 and continued to swing into 2023, now that I want a press conference to solve? This is as difficult as Xiao Xu getting married before the end of the year and performing a double transformation at the wedding.
Three Treasures Pharmacist bluntly said that yesterday's press conference only highlighted that the authorities had no planning at all, and even the original three-tong policy was an entire situation.
"In my opinion, pharmacists have to continue to work on their own!" To put it mildly, the magnesium oxide produced by the government project (soft stool, acid preparation, 110 years of health insurance use of 250 million pills), pharmacists will pay 33% for each order, because the cost of the project is much higher than the health insurance price.
The pharmacist who is serious about finding drugs to help patients is on the road of the Chao Pharma-Buddha. "There are three children in my family, and it is really impossible to be like the chairman of the board of directors who do not care about remuneration."
# Cai Government # Lack of Drugs # Food and Drug Administration # Ministry of Health and Welfare # Scrap

Jordanian hospitals face a medicine shortage due to a 300 million dinar debt to pharmaceutical companies.

Title:

Content: Lack of medicines in MOH hospitals and accumulation of indebtedness Repercussions / solutions
3 hours ago
Dr. Naeem Malkawi
The problem of shortage of medicines in Jordanian hospitals requires quick and effective attention and intervention, as providing medicines to patients is one of the foundations of quality health care and one of the most important strategies of the Ministry of Health, however, the shortage of medicines in many hospitals leads to health, economic and social challenges that threaten the quality of health care and patient safety.
The budget of the Ministry of Health of medicines, vaccines, vaccines and medical consumables for this year 2023 was estimated at 103.75 million dinars, where the actual for the past year 2022 was 93.8 million dinars.
The question is, how did the Ministry of Health accumulate such a large indebtedness in the item of medicines to reach 300 million dinars for pharmaceutical companies?
And why last week was the debt of 2019 cleared and deducted estimated at 50% of the debt for that year?
This means that there is still a delay in the payment of dues for companies for the years 2020, 2021 and 2022 in addition to eight months of the current year 2023, and this brings us to a range of reasons and challenges:
1.
The aim of the Ministry of Health was to reduce the bureaucracy of procedures and overcome the complexity of procurement references in hospitals and health directorates in the governorates and not to obtain price and discount preferences, but the results indicate a defect in the management and mechanism of dealing with the strategy of unified and central procurement, despite the margin for hospital administrations to use the power of direct purchase in cases of necessity.
2.
Preparation of sub-budgets for hospitals: Evidence shows that there is a problem in the preparation of sub-budgets for hospitals and the main budget of the Ministry of Health with regard to the item of medicines, which is due to the lack of accurate and sufficient data on the number of patients and hospital needs of medicines, and the lack of accurate forecasting of future needs.
3.
Delays in the review of financial claims and invoices between the Ministry of Health and the hospitals on the one hand and the pharmaceutical companies on the other hand, is one of the most important reasons behind the accumulation of indebtedness, and this negatively affects the liquidity of the pharmaceutical companies and hinders them from providing a sustainable service in adhering to the procedures of supplying medicines according to schedule.
4.
Lack of coordination and communication: There may be a lack of coordination and communication between hospitals, the Ministry of Health and pharmaceutical companies, which complicates the supply and distribution of medicines and increases the chances of delays and the depletion of medicines from hospitals in the absence of an effective policy for stock management and the time required for stock adequacy.
5.
Focusing on the trade names of certain drugs from specific production sources and not adopting the protocol of writing the scientific name for the prescriptions of patients.
6.
One of the reasons that may be major and important at the same time is the funding aspect and the lack of the necessary allocations or use them in other aspects other than medicines to fill a deficit or emergency during the use of budget items due to the scarcity of available liquidity. Medication.
Lack of medication can lead to:
1.
Threat to patient safety: Lack of medication puts sick people at risk, as this can lead to delays in receiving necessary treatment or the unavailability of vital drugs, putting their lives at risk.
2.
Economic Implications: The lack of medicines entails additional economic costs for the health system and patients.
Medical cases may be referred to other medical centers or private hospitals, increasing pressure on other MOH budget items.
3.
Pressure on health care workers: Health care workers are under pressure as a result of dealing with patients affected by drug shortages and repeatedly facing their inquiries and complaints.
4.
Social repercussions:
Increased anxiety and stress: A lack of medication can lead to an increase in anxiety and stress among patients and their families, as they live in uncertainty about the availability of the necessary treatment.
Lack of medication can affect the level of trust in the health system among citizens, who may feel that the system is unable to provide them with adequate health care.
Increased costs and social burdens: Some patients may have to incur additional costs to obtain drugs from other sources outside hospitals, affecting their financial and economic status.
After all this narrative there must be ways to overcome these dilemmas:
1.
Preparation of budgets scientifically and professionally: Hospitals should develop more accurate standards for the preparation of sub-budgets for medicines, through the analysis of previous data, estimation of future needs and other scientific and methodological foundations in the preparation of budgets and commitment to apply them accurately.
2.
Improve coordination and communication between parties: Coordination between the Ministry of Health, hospitals and pharmaceutical companies should be strengthened through the establishment of structured mechanisms for information exchange, review of invoices, and completion of claims, and not delay them.
3.
Implementation of fiscal reforms: The Government and the Ministry of Health should implement fiscal reforms that provide funding to cover this important item and pay dues in a timely manner, reduce bureaucracy in the financial audit process, and proceed with payment procedures within the timetable mechanism agreed in the tender terms.
4.
Achieving social responsibility: The government and pharmaceutical companies should adopt a social responsibility towards patients by providing these drugs and reducing their prices in the market to make them more accessible to patients while relieving part of the pressure and burden on hospitals.
Addressing the problem of drug shortages in government hospitals requires comprehensive cooperation between all concerned parties from government, Ministry of Health, hospitals, drug suppliers and patients.
To provide medicines on a permanent basis and to ensure the provision of high quality health care to the Jordanian patient.

Delays in payment to pharmaceutical companies have led to a medicine shortage, with unpaid debts from 2020 to August 2023.

Inadequate data on patient numbers and hospital needs has hindered sub-budget preparation for hospitals.

Poor coordination between hospitals, the Ministry of Health, and pharmaceutical companies has complicated medicine supply and distribution.

Funding issues have contributed to medication shortages.

Medication shortages can lead to threats to patient safety, economic implications, and increased stress on healthcare workers and patients.

Preparing budgets, improving coordination, and implementing reforms can help overcome medication shortages.

A shortage of essential medications is a significant issue in hospitals and pharmacies.

Title:

Content: Lubbock pharmacies struggling to keep important medication on the shelves

Shortage of antibiotics, cough syrup, and allergy medication
Published: Dec. 8, 2022 at 9:42 PM CST|Updated: 21 minutes ago

LUBBOCK, Texas (KCBD) - With more people getting sick this season, some pharmacies are having trouble keeping important medications in stock.

Soon, it may be hard to find simple things like antibiotics and cough medicine.

This can be a scary thought for a parent with a sick kid at home. Kelsie Hatchett is the mother of 4-year-old Briggs. Briggs has had strep at least three times this year. Kelsie says the thought of not being able to get what she needs in the future is scary.

“It seems like every day you’re hearing of another friend or family member who is sick and they’ve either got flu, they’ve got RSV, COVID, and respiratory illness,” Hatchett said. “So, it is a scary thing him getting sick and maybe he didn’t tolerate it as well that time.”

Jerad Thornhill is the owner of Thornhill’s Pharmacy’s in Shallowater and Lubbock. Antibiotics, cough medicines, and allergy medicines are flying off the shelves in his stores. He says on top of the high demand, all of these items are on back order.

“It’s been a real struggle to fulfill the majority of the prescriptions that are coming in for patients that are actively sick,” Thornhill said.

Trying to restock the shelves, Thornhill says he frequently checks with suppliers to see if anything is in stock. Then, checks with providers to find something comparable.

“Typically, we’re able to get someone taken care of that route,” Thornhill said. “The other option is a lot of times if something else is available we may have to order it and get it in for the next day.”

Every time you hear more sneezing and coughing around town, Thornhill says pharmacies experience shortages, but it’s never been like this.

“But for whatever reason this year it seems like it’s been, I don’t know if it’s still supply chain issues from COVID, or what it might be, but it’s this year in particular it seems to be quite a struggle,” Thornhill said.

Thornhill says there could be more than one problem affecting medicine making it to the stores.

“I think it’s a combination of supply chain and there are starting to be fewer and fewer manufacturers making some of these medications,” Thornhill said.

Kelsie is mom to Briggs, but she’s also a nurse. She says it’s important to make sure you absolutely need antibiotics before getting them so patients in the hospital have access.

“Now more than ever, it is important for us to take care of our bodies and really focus on letting them use those natural defenses to preserve those medications,” Hatchett said.

Hatchett says she understands wanting to treat children immediately; she shares that feeling as well, but she says it’s important to preserve that medication for everyone.

Thornhill says it’s not just cold and flu medications that are a problem currently. He says stores are low on ADHD medication and blood pressure medication as well.

High demand, especially during flu season, contributes to the shortage.

Essential medications are on backorder, making restocking difficult for pharmacies.

COVID-19 pandemic-related supply chain issues may be contributing to the medication shortage.

Fewer manufacturers producing certain medications contribute to the shortage.

Title:

Content: Lubbock pharmacies struggling to keep important medication on the shelves

Shortage of antibiotics, cough syrup, and allergy medication
Published: Dec. 8, 2022 at 9:42 PM CST|Updated: 21 minutes ago

LUBBOCK, Texas (KCBD) - With more people getting sick this season, some pharmacies are having trouble keeping important medications in stock.

Soon, it may be hard to find simple things like antibiotics and cough medicine.

This can be a scary thought for a parent with a sick kid at home. Kelsie Hatchett is the mother of 4-year-old Briggs. Briggs has had strep at least three times this year. Kelsie says the thought of not being able to get what she needs in the future is scary.

“It seems like every day you’re hearing of another friend or family member who is sick and they’ve either got flu, they’ve got RSV, COVID, and respiratory illness,” Hatchett said. “So, it is a scary thing him getting sick and maybe he didn’t tolerate it as well that time.”

Jerad Thornhill is the owner of Thornhill’s Pharmacy’s in Shallowater and Lubbock. Antibiotics, cough medicines, and allergy medicines are flying off the shelves in his stores. He says on top of the high demand, all of these items are on back order.

“It’s been a real struggle to fulfill the majority of the prescriptions that are coming in for patients that are actively sick,” Thornhill said.

Trying to restock the shelves, Thornhill says he frequently checks with suppliers to see if anything is in stock. Then, checks with providers to find something comparable.

“Typically, we’re able to get someone taken care of that route,” Thornhill said. “The other option is a lot of times if something else is available we may have to order it and get it in for the next day.”

Every time you hear more sneezing and coughing around town, Thornhill says pharmacies experience shortages, but it’s never been like this.

“But for whatever reason this year it seems like it’s been, I don’t know if it’s still supply chain issues from COVID, or what it might be, but it’s this year in particular it seems to be quite a struggle,” Thornhill said.

Thornhill says there could be more than one problem affecting medicine making it to the stores.

“I think it’s a combination of supply chain and there are starting to be fewer and fewer manufacturers making some of these medications,” Thornhill said.

Kelsie is mom to Briggs, but she’s also a nurse. She says it’s important to make sure you absolutely need antibiotics before getting them so patients in the hospital have access.

“Now more than ever, it is important for us to take care of our bodies and really focus on letting them use those natural defenses to preserve those medications,” Hatchett said.

Hatchett says she understands wanting to treat children immediately; she shares that feeling as well, but she says it’s important to preserve that medication for everyone.

Thornhill says it’s not just cold and flu medications that are a problem currently. He says stores are low on ADHD medication and blood pressure medication as well.

The shortage also affects ADHD and blood pressure medications.

Title:

Content: Lubbock pharmacies struggling to keep important medication on the shelves

Shortage of antibiotics, cough syrup, and allergy medication
Published: Dec. 8, 2022 at 9:42 PM CST|Updated: 21 minutes ago

LUBBOCK, Texas (KCBD) - With more people getting sick this season, some pharmacies are having trouble keeping important medications in stock.

Soon, it may be hard to find simple things like antibiotics and cough medicine.

This can be a scary thought for a parent with a sick kid at home. Kelsie Hatchett is the mother of 4-year-old Briggs. Briggs has had strep at least three times this year. Kelsie says the thought of not being able to get what she needs in the future is scary.

“It seems like every day you’re hearing of another friend or family member who is sick and they’ve either got flu, they’ve got RSV, COVID, and respiratory illness,” Hatchett said. “So, it is a scary thing him getting sick and maybe he didn’t tolerate it as well that time.”

Jerad Thornhill is the owner of Thornhill’s Pharmacy’s in Shallowater and Lubbock. Antibiotics, cough medicines, and allergy medicines are flying off the shelves in his stores. He says on top of the high demand, all of these items are on back order.

“It’s been a real struggle to fulfill the majority of the prescriptions that are coming in for patients that are actively sick,” Thornhill said.

Trying to restock the shelves, Thornhill says he frequently checks with suppliers to see if anything is in stock. Then, checks with providers to find something comparable.

“Typically, we’re able to get someone taken care of that route,” Thornhill said. “The other option is a lot of times if something else is available we may have to order it and get it in for the next day.”

Every time you hear more sneezing and coughing around town, Thornhill says pharmacies experience shortages, but it’s never been like this.

“But for whatever reason this year it seems like it’s been, I don’t know if it’s still supply chain issues from COVID, or what it might be, but it’s this year in particular it seems to be quite a struggle,” Thornhill said.

Thornhill says there could be more than one problem affecting medicine making it to the stores.

“I think it’s a combination of supply chain and there are starting to be fewer and fewer manufacturers making some of these medications,” Thornhill said.

Kelsie is mom to Briggs, but she’s also a nurse. She says it’s important to make sure you absolutely need antibiotics before getting them so patients in the hospital have access.

“Now more than ever, it is important for us to take care of our bodies and really focus on letting them use those natural defenses to preserve those medications,” Hatchett said.

Hatchett says she understands wanting to treat children immediately; she shares that feeling as well, but she says it’s important to preserve that medication for everyone.

Thornhill says it’s not just cold and flu medications that are a problem currently. He says stores are low on ADHD medication and blood pressure medication as well.

Using medications like antibiotics only when necessary helps preserve them for those who truly need them.

Title:

Content: Lubbock pharmacies struggling to keep important medication on the shelves

Shortage of antibiotics, cough syrup, and allergy medication
Published: Dec. 8, 2022 at 9:42 PM CST|Updated: 21 minutes ago

LUBBOCK, Texas (KCBD) - With more people getting sick this season, some pharmacies are having trouble keeping important medications in stock.

Soon, it may be hard to find simple things like antibiotics and cough medicine.

This can be a scary thought for a parent with a sick kid at home. Kelsie Hatchett is the mother of 4-year-old Briggs. Briggs has had strep at least three times this year. Kelsie says the thought of not being able to get what she needs in the future is scary.

“It seems like every day you’re hearing of another friend or family member who is sick and they’ve either got flu, they’ve got RSV, COVID, and respiratory illness,” Hatchett said. “So, it is a scary thing him getting sick and maybe he didn’t tolerate it as well that time.”

Jerad Thornhill is the owner of Thornhill’s Pharmacy’s in Shallowater and Lubbock. Antibiotics, cough medicines, and allergy medicines are flying off the shelves in his stores. He says on top of the high demand, all of these items are on back order.

“It’s been a real struggle to fulfill the majority of the prescriptions that are coming in for patients that are actively sick,” Thornhill said.

Trying to restock the shelves, Thornhill says he frequently checks with suppliers to see if anything is in stock. Then, checks with providers to find something comparable.

“Typically, we’re able to get someone taken care of that route,” Thornhill said. “The other option is a lot of times if something else is available we may have to order it and get it in for the next day.”

Every time you hear more sneezing and coughing around town, Thornhill says pharmacies experience shortages, but it’s never been like this.

“But for whatever reason this year it seems like it’s been, I don’t know if it’s still supply chain issues from COVID, or what it might be, but it’s this year in particular it seems to be quite a struggle,” Thornhill said.

Thornhill says there could be more than one problem affecting medicine making it to the stores.

“I think it’s a combination of supply chain and there are starting to be fewer and fewer manufacturers making some of these medications,” Thornhill said.

Kelsie is mom to Briggs, but she’s also a nurse. She says it’s important to make sure you absolutely need antibiotics before getting them so patients in the hospital have access.

“Now more than ever, it is important for us to take care of our bodies and really focus on letting them use those natural defenses to preserve those medications,” Hatchett said.

Hatchett says she understands wanting to treat children immediately; she shares that feeling as well, but she says it’s important to preserve that medication for everyone.

Thornhill says it’s not just cold and flu medications that are a problem currently. He says stores are low on ADHD medication and blood pressure medication as well.

The Ukraine-Russia conflict caused a 30-year high in drug shortages due to supply chain disruptions and raw material scarcity.

The Ukraine-Russia conflict caused a 30-year high in drug shortages due to supply chain disruptions and raw material scarcity.

The Ukraine-Russia conflict caused a 30-year high in drug shortages due to supply chain disruptions and raw material scarcity.

The FDA's limited release of certain raw materials, like ephedrine, causes a shortage of related drugs.

Title:

Content: The epidemic disrupted the supply chain, coupled with the shortage of raw materials caused by the war between Ukraine and Russia, caused the "biggest shortage of drugs in 30 years" in Taiwan at the beginning of last year. With the coming of the Chinese New Year, patients are worried about hoarding goods, and I am afraid that the shortage of drugs will become more serious.
A domestic pharmaceutical company recently received a call from a patient, the original patient has a heart disease, has been taking self-funded drugs, but recently faced the problem of lack of drugs, the doctor can not prescribe the same drugs, so the patient urgently asked the pharmaceutical company directly.
The drug factory staff, who did not want to be named, revealed that "it is not only this patient, but these patients even set up groups to find out where they can buy drugs, forcing them to call us after they have no way out."
Wang Ming-yuan, deputy spokesman of the All Federation of Pharmacists Association, said: "Last year, the shortage of drugs was the most serious situation since the outbreak of the epidemic, resulting in lack of labor and logistics. Now, with the release of the epidemic, the shortage of drugs has slowed down slightly.
For example, many patients with allergic rhinitis have been short of medicine for four months, Wang says, "Because it contains ephedrine, which is a controlled drug, the FDA only puts two batches of raw materials a year, so it is easy to run out of medicine.
Another reason for the shortage of drugs is the price of health insurance drugs. Due to the price cut, about 36% of the market share of "tears point eye" withdrew from the health insurance market in November last year. The drug used in the past in the health insurance annual consumption of more than 2.3 million bottles, which is equivalent to 190,000 bottles per month. And...
Shen Tsai-ying, a pharmacist, criticized officials for only treating head pain and foot pain. She said that the price of "love tears" health insurance is more expensive, health insurance has not saved money at all, and now even the domestically produced "Wufu" and other artificial tears brands are all out of stock.
Shen Caiying predicts that this wave of artificial tears shortage will continue until at least the Spring Festival.
Since the implementation of the "Drug Expenses Target System" (DET) in 102 years, the National Health Insurance Administration has set the target value of annual drug expenditure to maintain a stable and reasonable range of drug expenses. Under the total payment system, effective control of drug expenditure. Last year, the total drug price was reduced by 8.18 billion yuan, and the price of 5,500 drugs was reduced.
"The price of water and electricity is rising, but the price of health insurance has been cut!"
Shen Caiying pointed out that the price of drugs is constantly being cut, and pharmaceutical companies have no choice but to withdraw from the health insurance market, which has led to a more serious shortage of drugs.
In recent years, the Red Sea has been involved in the conflict between Israel and Hamas, and it has been attacked by Yemeni youth movement organizations, endangering the traffic of commercial ships. Large shipping companies have announced that they will stop sailing in the Red Sea and switch to the Cape of Good Hope in southern Africa, resulting in soaring freight costs. 180% increase.
Wang Ming-yuan laments that the situation at the freight gate will probably be the same as during the epidemic, and that the shortage of medicines will certainly increase, and with the arrival of the Chinese New Year, the public's "stockpiling" mentality will probably trigger a wave of drug snatching.
More CTWANT News
# Lack of medicine # Red Sea crisis # Lack of medicine # Original medicine

Price cuts have led pharmaceutical companies to withdraw from the health insurance market, causing a drug shortage.

The Red Sea conflict has increased freight costs by 180%, exacerbating the medicine shortage.

The US had a record 323 drug shortages in early 2024, surpassing the 2014 high of 320.

Title:

Content: Meitu
The first quarter of the United States serious drug shortage 323 drugs urgent cancer patients also have to be diverted and rationed!
CHU HENG NETWORK NEWS CENTER 2024-04-16 10: 42
According to the latest data from the American Society of Health System Pharmacists (ASHP) and the Utah Center for Drug Information Services, a total of 323 drugs in the United States were in severe shortages in the first quarter of this year, surpassing the record of 320 in 2014.
Among the drugs affected are the widely used diabetes drugs Ozempic and Mounjaro, the allergy treatment drug adrenaline, the common antibiotic amoxicillin for children, chemotherapy drugs and injections commonly used in hospitals in intensive care.
ASHP CEO Paul Abramowitz said in a statement that almost all categories of drugs are facing shortages, with non-patented sterile injectable drugs, including cancer chemotherapy drugs, and emergency drugs stored in hospital emergency vans and operating areas, the shortage of such drugs is the most worrying.
According to the American Cancer Society, chemotherapy is one of the top five drugs most affected by the shortage, which threatens to have a devastating impact on patients, and some hospitals and clinics say doctors have had to divert patients to ration their medications because of a shortage of some chemotherapy drugs.
In addition, ASHP noted that the continued nationwide shortage of ADHD drugs is “a problem for clinicians and patients. ”
The shortage of popular drugs is even more acute, with Mounjaro, the diabetes drug known as the “slimming pill ”, already in dire straits.
In response, Lilly said that the “unprecedented surge in demand ” for Mounjaro and its similar drug Zepbound has led to a shortage in the market, which the company is struggling to cope with.
Lilly is ramping up investments to boost production at Mounjaro and Zepbound in the second half of 2024.
The company said it expects intermittent supply disruptions in the near term due to unprecedented demand.
How to cure the drug shortage
The last major “drug shortage ” in U.S. history occurred in 2014, and it has only been alleviated in the years since.
Since 2021, the drug shortage situation seems to be increasing, and scholars in the field of medical health and economics in the United States believe that the reason for most drug shortages in the United States is the fragmentation of the drug supply chain.
The White House this month proposed spending between $3.26 billion and $5.11 billion over the next decade to help address the nation ’ s drug shortage.
The bill requires approval and funding from the U.S. Congress.
U.S. researchers and policymakers believe that a complete solution to the “drug shortage ” may require changes to the business model of the U.S. pharmaceutical industry, including measures to increase the price of generic drugs to attract more drug manufacturers.
Policymakers recommend giving the FDA more power to access more information about drug shortages and impending shortages.
Currently, the FDA relies primarily on phone calls to manufacturers asking if they can increase their supply to understand the situation.
The American Society of Health System Pharmacists said it is working with the federal government to advise the government on measures to address the drug shortage, including that Congress should require manufacturers to be more transparent on any supply chain issues and encourage more diversity in supply chains.
According to Abramowitz, “The federal government still has a lot of work to do to fundamentally address drug shortages, and the American Society of Health System Pharmacists will continue to engage regularly with policymakers to guide them in drafting and passing new legislation to address drug shortages and continue to advocate vigorously for proven solutions on behalf of our members. ”

The shortage affected various drug categories, including diabetes, allergy, antibiotic, chemotherapy, and emergency medications.

Sterile injectable drugs, including cancer chemotherapy, were among the most worrying shortages.

The shortage of chemotherapy drugs has devastated patients, forcing hospitals to ration medications.

A nationwide shortage of ADHD drugs persists.

Demand for drugs like Mounjaro has led to shortages due to manufacturers' struggles to keep up with production.

Fragmentation of the US drug supply chain contributes to drug shortages.

The White House proposes spending $3.26 billion to $5.11 billion over the next decade to address the nation's drug shortage.

U.S. researchers and policymakers believe a complete solution to the drug shortage may require changes to the U.S. pharmaceutical industry's business model.

Policymakers recommend giving the FDA more power to access drug shortage information.

Hospitals have struggled with medication shortages, rising costs, and falling revenues between 2021 and 2024.

Hospitals have struggled with medication shortages, rising costs, and falling revenues between 2021 and 2024.

Hospitals have struggled with medication shortages, rising costs, and falling revenues between 2021 and 2024.

The COVID-19 pandemic has worsened healthcare system issues, including staffing shortages and rising medication and PPE costs.

Title:

Content: Health Care Special Coverage

Hospitals Challenged by Rising Costs, Falling Revenues

Critical Condition

An “inflection point.”

That’s what Dr. Robert Roose says hospitals have reached when it comes to their bottom lines and the ongoing challenge of making ends meet at a time when revenues continue to fall and expenses continue to rise.

Hospitals have perpetually struggled from a fiscal standpoint amid continually rising prices, the need to constantly upgrade technology and innovate, and reimbursement rates from payers that have historically been below 80 cents on the dollar, Roose said. But trends and conditions that existed before the pandemic have only been exacerbated over the past three years, and now, hospitals are at a critical, and extremely challenging, crossroads.

“There’s no way to sugarcoat it — hospitals and health systems across Massachusetts, and across the majority of the country, are finding themselves struggling in many regards, and at an inflection point where there are going to need to be continued efforts to support hospitals, or there will continue to be systems and hospitals that remain in distress,” said Roose, chief administrative officer at Mercy Medical Center in Springfield, part of Trinity Health Of New England.

He quantified the situation by noting that Mercy is on a path to lose roughly $25 million for the fiscal year that will end in June, about the same amount as last year.

“There’s no way to sugarcoat it — hospitals and health systems across Massachusetts, and across the majority of the country, are finding themselves struggling in many regards, and at an inflection point where there are going to need to be continued efforts to support hospitals, or there will continue to be systems and hospitals that remain in distress.”

Dr. Robert Roose

“It will be challenging to persist with the current models that are in place in the same ways that we have in the past,” Roose went on. There are a multitude of reasons for that, but the challenges remain significant, and the pathways forward are going to require multiple initiatives and ongoing support from a variety of different angles.

Dr. Lynette Watkins, president and CEO of Cooley Dickinson Hospital, an affiliate of Mass General Brigham, agreed, noting that COVID put the challenges that all hospitals are facing under a brighter spotlight.

“The past three years have been particularly challenging,” she said, citing everything from staffing issues to the aging of the population and the pressures they put on hospitals. “What COVID laid bare is that all of these issues are there, and that it’s incumbent on us to be creative, accelerate the solutions, and leverage a lot of the tools that we were in many ways reticent to use, such as telehealth and virtual visits.

“While this situation has challenged us, it has also provided us with an opportunity to think differently, to treat patients differently, to engage differently — with our patients and with the community,” Watkins went on, adding that she and her team at CDH are working to taking full advantage of that opportunity.

Spiras Hatiras, president and CEO on Holyoke Medical Center (HMC), concurred. In remarks made to BusinessWest for its annual Economic Outlook, he spoke of both challenge and opportunity, on several fronts, but especially when it comes to workforce issues.

The ongoing workforce crisis, while it has impacted all sectors, has put healthcare providers, and especially hospitals, at an extreme disadvantage, especially when it comes to nursing and the need to fill vacancies with contract or ‘travel’ nurses, which can cost two or three times what a staff nurse might, Hatiras noted.

“In healthcare, there is a great deal of concern, and the most concerning part is the continuing shortage of personnel, which has created this market for temporary staffing at rates that are truly outrageous,” he said. “To put things in perspective, we have about 20 nurses on temporary staff that we get through agencies. Those 20 nurses, on an annual basis, cost us $5 million; each nurse costs us $250,000 because the rates are exorbitant — the nurses get a lot of money, but there’s also a middleman that makes untold amounts of money from this crisis.

“As a nation, the federal government is doing a lot of things — they did some things with railroad workers, they’re helping Ukraine, they’re talking about a lot of things. They should have stepped in and regulated this and said, ‘the pandemic created a tremendous amount of shortage; we cannot allow private companies to go out and profit from that shortage of staffing and bring hospitals to their knees.’ With all this, it’s going to be very difficult for hospitals to cope, and that’s why all our strategy centers around finding a way to attract nurses here.”

For this issue, BusinessWest takes an in-depth look at the fiscal challenges facing hospitals today, and what must happen for these institutions to weather this severe storm.

Dollars and Sense

When asked how hospitals arrived at this inflection point, as he called it, Roose said it was a combination of factors, but, as he and others noted earlier, it comes down to an exacerbation of, to borrow an industry term, some pre-existing conditions.

These include a trend toward outpatient, rather than inpatient, care, which certainly impacts overall revenues, and also shortages on the workforce front, which increase the cost of doing business in many ways, and sharp rises in prices of … well, just about everything, from medications to PPE.

“What COVID laid bare is that all of these issues are there, and that it’s incumbent on us to be creative, accelerate the solutions, and leverage a lot of the tools that we were in many ways reticent to use, such as telehealth and virtual visits.”

Dr. Lynette Watkins

“We’ve been dealing with the aftershocks of one of the most significant public-health crises of our time,” Roose explained. “And it occurred at a point where many shifts in healthcare were already underway, including a shift from inpatient care toward the delivery of care in a lower-cost outpatient, ambulatory setting where the trends of consumers, our patients, were beginning to change, but where the reimbursement for those services had not been able to keep up with those changes. This was layered on top of an existing healthcare-workforce shortage.

“So, the pandemic caused a significant challenge amidst what was already several headwinds that were providing stiff challenges for smaller hospitals across the country to overcome,” he went on, “forcing them to transform, to look differently, to meet those challenges and the needs of our community.”

Elaborating, he turned the clock back to late 2019 for perspective. He said that there was already significant movement in how healthcare was being delivered. More services were being provided in settings outside hospitals, he explained, with surgeries taking place in outpatient, ambulatory settings. Meanwhile, insurance companies were adjusting as well, covering certain types of procedures, such as joint replacements, only if they took place in those lower-cost settings.

“With that, inpatient volume was beginning to decline by a few percentage points,” Roose said, adding that those shifts were beginning to accelerate when the pandemic hit. Overall, there has been movement away from the fee-for-service model that had dominated healthcare delivery for decades and a shift toward promoting wellness, he explained, but not enough movement to shelter hospitals, especially smaller community hospitals, from those headwinds he described earlier.

“It has certainly not kept pace with the dramatic impact on volume and the lack of reimbursement for fee-for-service care that has occurred to make up that gap,” he went on, adding that staffing shortages already existed before the pandemic, but they, too, were exacerbated by COVID and its many side effects.

Watkins agreed, and, like others we spoke with, she said revenues have certainly improved since the depths of the pandemic, but they are still not at pre-COVID levels.

And there are many other forces at play that are challenging hospitals, she added, including a shortage of workers at post-acute facilities such as nursing homes, which often leaves patients who are otherwise ready for discharge with no place to go, putting more pressure on hospitals.

“We have two, three, or sometimes more patients who are ready for medical discharge, but when we don’t have a place to send those patients, so they stay with us,” Watkins said. “And that means that some patients who need to in an acute-care facility are in the emergency room or cannot get in; that’s been a huge, huge challenge.”

Work in Progress

One of the factors greatly impacting hospital finances is the ongoing workforce crisis, which has certainly increased the cost of providing care. Roose told BusinessWest that, while Mercy’s overall workforce is down perhaps 20%, due to a variety of factors, its workforce costs are still 7% to 8% higher than before the pandemic.

Indeed, with many positions, not just nurses, hospitals have had to rely on contract employees, which are considerably more expensive than those on staff.

“In healthcare, there is a great deal of concern, and the most concerning part is the continuing shortage of personnel, which has created this market for temporary staffing at rates that are truly outrageous.”

Spiros Hatiras

But there are other factors as well, said Watkins, including additional overtime, bonuses needed to attract job candidates, shift bonuses, and more.

“It’s a huge challenge, and it significantly affected our financial performance, as well as that of other systems in the Commonwealth and across the country,” she said. “And we have to make sure that we are staffed to take care of the patients here that are sicker and that are staying longer.”

Elaborating, she explained that Cooley Dickinson used very few contract nurses prior to the pandemic, but the need for such personnel has risen dramatically due to retirements, burnout, and individuals simply leaving the profession to do something else.

These forces have left hospitals to fill the gaps as best they can and, for the long term, focus energies — or even more energies, as the case may be — on attracting and retaining personnel across the board.

Indeed, Hatiras told BusinessWest that closing the staffing gap is critical because it will bring down the overall cost of doing business and help hospitals cope with lower amounts of COVID relief and revenue levels still below those from before the pandemic.

“With ARPA funds drying up, we’re going to have pull ourselves up by our bootstraps. So our emphasis is on closing the staffing gap,” he said. “If we can do that, and not bleed money on the expense side, I think we’ll be OK; I think we’re poised to have a good year, as long as we’re able to attract nurses here.”

Elaborating, he said closing this gap involves making HMC a preferred place to work, one where applicants with choices will want to go — and hopefully stay, thus reducing the high cost of continually filling vacancies.

“We’re doing OK because we had to respond to what was going on in the market by creating even more attractive reasons for coming here — we raised our rates, we’re enhancing benefits, and at the same time, we’re looking at economic assistance for the lower-earning employees,” he said. “Where it’s more difficult is with the professionals because the dollars are significantly more, so competing just on price is difficult. The key for success — what keeps people here and makes them come here — is the culture of the place, so we put a tremendous amount of effort in the 10 years I’ve been here on creating a good culture. Now, it’s become a differentiator, and we’re pushing it even more. We’re an employer that listens to employees, responds to their needs, and cares. That’s what people want.”

Roose concurred, and told BusinessWest that the recent challenges that hospitals have faced have put even more emphasis on the importance of people in the overriding task of providing quality care to patients — and the overall success of a provider.

“Never has it been more apparent, and critical, to realize that people are the vehicles through which we deliver healthcare,” he said. “We do not deliver services that can be provided by machines; we’re reliant upon the great skills of care providers — and we don’t take that lightly.”

Bottom Line

Moving forward, Roose said, as hospitals cope with these various challenges — and, again, there are many of them — state and federal governments need to step up and continue to provide needed support.

“The ARPA funding and other sources of relief through the pandemic and beyond, which is greatly appreciated, is not enough to close the gap from the challenges that we have encountered,” he noted. “The cost structure for delivering care has increased so dramatically, the models for fee-for-service care have not shifted quick enough, and the rates from commercial and other payers has not kept up with inflation.

“So even with all that support, hospitals like Mercy Medical Center are expected to lose about $25 million this year, which is very similar to what it was the year before, and Trinity Health Of New England lost $65 million in fiscal 2022 from operations,” he went on. “And that puts incredible stress on hospitals.”

Indeed, it does, and these losses, and the forces behind them, explain why hospitals are at an inflection point, and why change is needed if they are to move from critical condition fiscally to something far more sustainable.

Related Posts

buy ivermectin for humans buy ivermectin online
buy generic cialis buy cialis

Hospitals face high costs for temporary staffing, with contract nurses often costing two to three times more than staff nurses.

Staffing shortages, including a nurse shortage, have increased care costs and pressured hospitals to find creative solutions.

Governments must continue to support hospitals as they face various challenges.

Ireland had a paracetamol shortage in 2023 due to a surge in Covid-19 and flu cases.

Title:

Content: Ireland has been suffering a paracetamol shortage as cases of Covid-19 and the winter flu in the country soared over the festive and new year period.

The revelation was made by Health Minister Stephen Donnelly after his department received notification of a supply issue from the Health Products Regulatory Authority.

It is understood the shortage impacted some prescription paracetamol products.

Read More:Irish people complain of ‘worst ever’ winter bug sweeping country that feels like Covid but isn’t

Two suppliers affected have stated that resupply will be sometime in January 2023.

However, there are other prescription paracetamol suppliers with some stock available on the shelves.

Paracetamol is one of the medicines used most often in Ireland and especially for the flu, aches and pain.

But Mr Donnelly pointed out that there are multiple forms of the drug with different strengths and brands available from various sources.

He said: "In the event that there are some supply issues for individual medicines, alternative options such as alternative strengths and brands, generic medicines will usually be available to ensure continuity of treatment.

"In some cases where the medicine initially prescribed for the patient is unavailable, patients may be switched to a suitable therapeutic alternative following appropriate consultation with a healthcare professional."

The Health Minister said medicine shortages have been increasingly prevalent worldwide over the past decade. The causes of such shortages are multifactorial including shortage of raw materials, manufacturing difficulties and industry consolidations.

He stated: "Medicine shortages can originate at any point in the supply chain. They can involve and impact many stakeholders in different ways as the supply models and clinical use of therapies can vary across national health systems.

"Management of medicines shortages necessitates a multi-faceted, multi stakeholder response to ensure patient safety , continuity of care and protection of public health.

"Patients or their carers who have any concerns in relation to temporary alternative products provided because of medical shortages are advised to speak with their pharmacist or other healthcare [professionals] involved in their care."

Mr Donnelly was responding to a number of written Dail questions on the shortage of medicines.

READ NEXT:

Get breaking news to your inbox by signing up to our newsletter

The shortage affected some prescription paracetamol products, but alternatives were available.

Title:

Content: Ireland has been suffering a paracetamol shortage as cases of Covid-19 and the winter flu in the country soared over the festive and new year period.

The revelation was made by Health Minister Stephen Donnelly after his department received notification of a supply issue from the Health Products Regulatory Authority.

It is understood the shortage impacted some prescription paracetamol products.

Read More:Irish people complain of ‘worst ever’ winter bug sweeping country that feels like Covid but isn’t

Two suppliers affected have stated that resupply will be sometime in January 2023.

However, there are other prescription paracetamol suppliers with some stock available on the shelves.

Paracetamol is one of the medicines used most often in Ireland and especially for the flu, aches and pain.

But Mr Donnelly pointed out that there are multiple forms of the drug with different strengths and brands available from various sources.

He said: "In the event that there are some supply issues for individual medicines, alternative options such as alternative strengths and brands, generic medicines will usually be available to ensure continuity of treatment.

"In some cases where the medicine initially prescribed for the patient is unavailable, patients may be switched to a suitable therapeutic alternative following appropriate consultation with a healthcare professional."

The Health Minister said medicine shortages have been increasingly prevalent worldwide over the past decade. The causes of such shortages are multifactorial including shortage of raw materials, manufacturing difficulties and industry consolidations.

He stated: "Medicine shortages can originate at any point in the supply chain. They can involve and impact many stakeholders in different ways as the supply models and clinical use of therapies can vary across national health systems.

"Management of medicines shortages necessitates a multi-faceted, multi stakeholder response to ensure patient safety , continuity of care and protection of public health.

"Patients or their carers who have any concerns in relation to temporary alternative products provided because of medical shortages are advised to speak with their pharmacist or other healthcare [professionals] involved in their care."

Mr Donnelly was responding to a number of written Dail questions on the shortage of medicines.

READ NEXT:

Get breaking news to your inbox by signing up to our newsletter

Medicine shortages have increased worldwide over the past decade due to raw material shortages, manufacturing difficulties, and industry consolidations.

Title:

Content: Ireland has been suffering a paracetamol shortage as cases of Covid-19 and the winter flu in the country soared over the festive and new year period.

The revelation was made by Health Minister Stephen Donnelly after his department received notification of a supply issue from the Health Products Regulatory Authority.

It is understood the shortage impacted some prescription paracetamol products.

Read More:Irish people complain of ‘worst ever’ winter bug sweeping country that feels like Covid but isn’t

Two suppliers affected have stated that resupply will be sometime in January 2023.

However, there are other prescription paracetamol suppliers with some stock available on the shelves.

Paracetamol is one of the medicines used most often in Ireland and especially for the flu, aches and pain.

But Mr Donnelly pointed out that there are multiple forms of the drug with different strengths and brands available from various sources.

He said: "In the event that there are some supply issues for individual medicines, alternative options such as alternative strengths and brands, generic medicines will usually be available to ensure continuity of treatment.

"In some cases where the medicine initially prescribed for the patient is unavailable, patients may be switched to a suitable therapeutic alternative following appropriate consultation with a healthcare professional."

The Health Minister said medicine shortages have been increasingly prevalent worldwide over the past decade. The causes of such shortages are multifactorial including shortage of raw materials, manufacturing difficulties and industry consolidations.

He stated: "Medicine shortages can originate at any point in the supply chain. They can involve and impact many stakeholders in different ways as the supply models and clinical use of therapies can vary across national health systems.

"Management of medicines shortages necessitates a multi-faceted, multi stakeholder response to ensure patient safety , continuity of care and protection of public health.

"Patients or their carers who have any concerns in relation to temporary alternative products provided because of medical shortages are advised to speak with their pharmacist or other healthcare [professionals] involved in their care."

Mr Donnelly was responding to a number of written Dail questions on the shortage of medicines.

READ NEXT:

Get breaking news to your inbox by signing up to our newsletter

Managing medicine shortages requires a multi-faceted response to ensure patient safety.

Title:

Content: Ireland has been suffering a paracetamol shortage as cases of Covid-19 and the winter flu in the country soared over the festive and new year period.

The revelation was made by Health Minister Stephen Donnelly after his department received notification of a supply issue from the Health Products Regulatory Authority.

It is understood the shortage impacted some prescription paracetamol products.

Read More:Irish people complain of ‘worst ever’ winter bug sweeping country that feels like Covid but isn’t

Two suppliers affected have stated that resupply will be sometime in January 2023.

However, there are other prescription paracetamol suppliers with some stock available on the shelves.

Paracetamol is one of the medicines used most often in Ireland and especially for the flu, aches and pain.

But Mr Donnelly pointed out that there are multiple forms of the drug with different strengths and brands available from various sources.

He said: "In the event that there are some supply issues for individual medicines, alternative options such as alternative strengths and brands, generic medicines will usually be available to ensure continuity of treatment.

"In some cases where the medicine initially prescribed for the patient is unavailable, patients may be switched to a suitable therapeutic alternative following appropriate consultation with a healthcare professional."

The Health Minister said medicine shortages have been increasingly prevalent worldwide over the past decade. The causes of such shortages are multifactorial including shortage of raw materials, manufacturing difficulties and industry consolidations.

He stated: "Medicine shortages can originate at any point in the supply chain. They can involve and impact many stakeholders in different ways as the supply models and clinical use of therapies can vary across national health systems.

"Management of medicines shortages necessitates a multi-faceted, multi stakeholder response to ensure patient safety , continuity of care and protection of public health.

"Patients or their carers who have any concerns in relation to temporary alternative products provided because of medical shortages are advised to speak with their pharmacist or other healthcare [professionals] involved in their care."

Mr Donnelly was responding to a number of written Dail questions on the shortage of medicines.

READ NEXT:

Get breaking news to your inbox by signing up to our newsletter

Only about 400 treatments exist for over 7,000 known rare diseases, causing a global medication shortage.

Title:

Content: Health · Life
Let rare disease patients have a doctor, medicine, and protection
Li He
January 11, 2023 07: 51 Source: Science and Technology Daily
53%
In recent years, relevant departments have strongly supported the prevention and protection of rare diseases, and strengthened the supply of rare diseases research, diagnosis and treatment and drug research and development.
According to statistics, as of the end of November 2022, 89 drugs for the treatment of 45 rare diseases have been approved in China, and the number of rare diseases that can be treated in China accounts for 53% of the number of rare diseases that can be treated in the world.
On January 8 this year, the on-site negotiations on the national medical insurance drug catalog in 2022 were officially concluded.
Among them, 19 drugs for rare diseases, including Fabric's disease, Pompeii's disease, Gosher's disease, pulmonary hypertension and spinal muscular atrophy, set a new record.
Rare diseases are also called "orphan diseases".
According to the definition given in the "China Rare Disease Definition Research Report 2021", diseases with a neonatal incidence of less than one in 10,000, a prevalence of less than one in 10,000, and a number of diseases with a disease of less than 140,000, can be rare diseases.
Although the incidence of rare diseases is extremely low, but there are many kinds of diseases, the total number of patients is not a lot.
As of February 2022, there are more than 20 million rare disease patients in China, and more than 200,000 new patients are added every year.
Qiao Jie, an academician of the Chinese Academy of Engineering and executive vice president of Peking University, said that more than 7,000 rare diseases have been found in the world, about 80 percent of which are hereditary diseases and about 50 percent of which occur in childhood.
"Disease without medicine", "medicine without medicine" and "medicine without insurance" are common "crux" faced by patients with rare diseases.
Build a network of diagnosis and treatment, solve the problem of "no medical care"
Because rare diseases are rare and the number of patients with a single disease is very small, doctors, especially grass-roots hospitals, have insufficient ability to recognize and diagnose rare diseases, which restricts the improvement of rare diseases diagnosis and treatment ability.
The first step in the treatment of diseases is correct diagnosis, and difficult to diagnose is the first difficulty encountered by rare disease patients. In September 2021, a rare disease patient weighing only 18 kg was admitted to Beijing University of Aeronautics and Astronautics.
A Beijing doctor who happened to return to his hometown to visit his family suggested that he go to Peking University First Hospital for detailed investigation, so that sail, who is suffering from congenital muscular dystrophy, has an opportunity for early treatment.
According to the "2020 China Rare Disease Comprehensive Social Survey" released by the China Rare Disease Alliance, 15.5% of the more than 20,000 patients participating in the survey need to experience 1-4 years of diagnosis, and 5% of patients need to experience 5-20 years of diagnosis, with an average diagnosis time of 4.26 years.
Of these, 42% also experienced a misdiagnosis.
In order to improve the diagnosis and treatment of rare diseases, in 2018, the five departments of the National Health and Health Commission, the Ministry of Science and Technology, and the Ministry of Industry and Information Technology jointly issued the "First Catalogue of Rare Diseases". 121 diseases were included in the list of rare diseases. In October 2019, China launched the registration of rare disease diagnosis and treatment information. In February 2020, the office of the national rare disease diagnosis and treatment network was officially established.
The implementation of a series of policies has made the diagnosis and treatment of rare diseases in China continue to improve.
Zhang Liyang, president of Beijing Union Hospital and deputy director of the office of the National Rare Disease Diagnosis and Treatment Network, said that as the national leading hospital of the National Rare Disease Diagnosis and Treatment Network, in 2018 Beijing Union Hospital set up a multi-disciplinary consultation platform for rare diseases, which has registered 93 rare diseases in the National Rare Disease Direct Reporting System, involving more than 60,000 cases.
With the support of all parties, Beijing Union Hospital has taken the lead in carrying out many training sessions in many parts of the country, involving more than 80 rare diseases and covering more than 50,000 doctors.
Strengthen drug research and development and get rid of the dilemma of "medicine without medicine"
Due to the small market demand, difficult research and development, high cost and long cycle, there are not many pharmaceutical companies involved in the R & D and production of rare disease drugs, which leads to less rare disease drugs, known as "orphan drugs".
The data show that of the more than 7,000 rare diseases currently known, there are no more than 400 corresponding treatment drugs.
Strengthening the research and development of rare diseases is an important part of helping the treatment of rare diseases.
Domestic pharmaceutical companies are already working in this area.
Beihai Kangcheng, Kantini Pharmaceutical, Deyi Sunshine Bio, Shufang Medicine, Luang Yu Group, Faith Pharmaceutical Technology, etc. have invested huge funds and energy in the field of rare diseases drugs.
Beihaikang, for example, has received an exclusive global license from the Massachusetts State University School of Medicine to develop, produce and commercialize a new second-generation gene therapy for spinal muscular atrophy.
Huang Guo, deputy director of the State Drug Administration, said that we need to continue to promote rare disease drug research and development innovation in the future, and encourage foreign innovative drugs to synchronously research and development, clinical and synchronous declaration in China, and strive to synchronize the listing, so that rare diseases patients in China can use drugs faster and use good drugs.
In recent years, relevant departments have strongly supported the prevention and protection of rare diseases, and strengthened the supply of rare diseases research, diagnosis and treatment and drug research and development.
According to statistics, as of the end of November 2022, 89 drugs for the treatment of 45 rare diseases have been approved in China, and the number of rare diseases that can be treated in China accounts for 53% of the number of rare diseases that can be treated in the world.
The introduction of multiple guarantees to reduce the worry of "drug no guarantee"
"Although the incidence of rare diseases is extremely low, the cost of medical treatment is very high, and the annual cost of medical treatment for rare diseases can reach tens of millions of yuan," said Shan Xiaoou, a member of the Rare Disease Group of the Chinese Medical Association.
In addition, medical insurance reimbursement is difficult, and many drugs for rare diseases with extremely high prices are not included in the list of basic medical insurance drugs.
Most of the medicines cannot be reimbursed by the basic medical insurance and the major diseases insurance fund, and they can only pay for themselves.
In order to enable more rare disease patients to afford drugs, the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue (2021) has included 58 rare disease drugs, accounting for about 67% of the listed rare disease drugs.
For example, Nocina sodium injection, which used to be 700,000 yuan per needle, was included in medical insurance after medical insurance negotiations with more than 30,000 yuan, and children with spinal muscular atrophy became "lucky children".
Various localities have also actively explored the mechanism of drug protection.
More than 10 provinces and cities across the country have set up drug protection mechanisms involving high-value drugs for rare diseases, including special funds, major medical insurance, financial contributions, medical assistance, and policy-oriented commercial insurance.
In many places, it is not just a single system guarantee, but by the government, the market and society to provide multiple guarantees, supplementing the national basic medical insurance, and realizing the "access to medication" of rare disease patients who need high-value drug treatment.
For example, Zhejiang is the first province to introduce a provincial medical guarantee mechanism for rare diseases. In 2015, according to the economic and social development level of Zhejiang Province, the balance of medical insurance fund and the diagnosis and treatment of rare diseases.
In terms of commercial supplementary medical insurance, the "West Lake Benefit Joint Insurance" has set up special medical insurance for three rare diseases such as spinal muscular atrophy.
The medical insurance will be paid at a rate of 60 percent after deducting the initial payment line of 10,000 yuan for the year, and the maximum payment limit for the year will be 100,000 yuan.
Related Links
Rare diseases must be prevented.
"There are many kinds of birth defects, there are more than 8,000 kinds, a considerable proportion of which are rare diseases." Song Li, director of the Department of Maternal and Child Health of the National Health and Health Commission, said that the number of pre-screening institutions in China has reached more than 4,800, prenatal diagnostic institutions reached 498, and newborn genetic and metabolic disease screening institutions have been popularized in many provinces and cities.
Song Li pointed out that rare diseases should be prevented and controlled from the source.
China has adopted three levels of prevention and control measures to prevent birth defects, and has moved forward through marriage, childbirth and newborn screening, so as to ensure early detection, early intervention and early treatment, and reduce the incidence of rare diseases.
"In the case that more than 90% of rare diseases are not solved, prevention is the most cost-effective health strategy," Yu Xuejun, deputy director of the National Health Commission, said.
(Editor: Sun Hongli, Yang Di)
Related News

China has approved 89 drugs for 45 rare diseases, covering 53% of globally treatable rare diseases.

The cost of medical treatment for rare diseases can be very high, reaching tens of millions of yuan annually.

Many rare disease drugs are not covered by basic medical insurance, making them unaffordable for patients.

China has set up mechanisms, including funds and insurance, to help rare disease patients access expensive drugs.

China has set up mechanisms, including funds and insurance, to help rare disease patients access expensive drugs.

China has set up mechanisms, including funds and insurance, to help rare disease patients access expensive drugs.

The IV paracetamol shortage is expected to last until at least November due to manufacturing capacity constraints.

Title:

Content: Hospitals spanning England face critically low levels of intravenous paracetamol - as a national shortage of the popular painkiller runs on. Paracetamol administered via an IV is the safest and most effective drug to give patients who are in post-operation pain - but staff at one hospital trust in particular have been told to pull the plug on the drug from anaesthetic rooms immediately.

The shortage of IV paracetamol is expected to run into November at earliest, with a Department for Health and Social Care spokesman blaming 'capacity constraints with a manufacturer' as the cause. One hospital worker detailed how deeply worried they were at the shortage - citing how it is much more effective than the orally consumed version.

They said: "It is deeply worrying. We use IV paracetamol because tablets taken orally are only 30% effective. Given by IV it is a potent and direct drug and it restricts pain very quickly."

Read more: Doctor warns that silent pandemic 'scarier' than Covid-19 is already killing a million a year

It is reported by The Mirror that they went on: "The alternatives are oral morphine, which is very slow-acting, or nonsteroidal anti-inflammatories such as ibuprofen and aspirin, which can have negative side effects such as bleeding and allergic reactions."

Drug shortages have become a global problem, worsened by the recent Covid pandemic, the ongoing war in Ukraine, the energy crisis and record levels of inflation. Last winter, France completely culled the internet sales of paracetamol products in a widespread shortage blamed on a Chinese export ban on raw materials.

In Great Britain meanwhile, it is Brexit which is primarily blamed for making matters worse. This is because drug imports from the EU - which historically make up two thirds of the National Health Service's supply - are at their lowest ever levels since leaving.

The health department’s spokesman, said: "Guidance has been issued to the NHS advising on how to manage the issue and we are working with those in the supply chain to resolve this as soon as possible."

Labour’s shadow health minister, Liz Kendall, said: "Concerned staff and patients will understandably be seeking reassurance that the pain relief they need is available. The Government must spell out the urgent steps being taken to resolve the shortage."

It comes after a Covid Inquiry heard that a lack of nurses left the NHS and Great Britain vulnerable to the pandemic - with the infection control lead at the Royal College of Nursing telling of a national shortage of PPE due to a lack of planning for an airborne virus.

Rosemary Gallagher, the RCN’s professional lead for infection prevention and control, explained: "The resilience of the health and care workforce is absolutely essential in order to be able to deliver health care services that meet the public's needs. We know that we went into the pandemic with a significant shortage, about 50,000 nurses short.

"That immediately put us at risk when we needed to surge capacity to support patients at home and in hospitals."

The intervention came the same day that a damning international study warned that Britain has fewer nurses than other developed nations.

Drug shortages have become a global problem, worsened by the Covid pandemic, the Ukraine war, and economic crises.

The Covid pandemic has worsened the global medication shortage.

The war in Ukraine has worsened the global medication shortage.

The energy crisis has worsened the global medication shortage.

Inflation has worsened the global medication shortage.

Brexit has worsened Great Britain's medication shortage problem.

EU drug imports, which make up two-thirds of the NHS's supply, are at a record low since Brexit.

The global medication shortage has persisted from 2021 to 2024 with no end in sight.

The FDA reported 111 US drug shortages as of December 2021.

Title:

Content: US supply chain crisis continues, FDA points to 111 drug shortages
Global Social Hotspot 16: 35 2021 / 12 / 05
Share:
The supply chain crisis in the United States continues, and many goods are facing shortages.
The US media said that the US pharmacies have a number of critical prescription drugs in stock. The US Food and Drug Administration (FDA) pointed out that about 111 drugs are out of stock in the United States. The FDA stressed that it will continue to take measures to monitor the supply chain.
【 Omicron variant 】 Travellers must have a negative test within 48 hours for entering the United Kingdom 【 Next 】
The Federal Reserve warned on Wednesday that large parts of the United States had begun to be affected by supply chain disruptions and labor shortages last month.
According to the FDA website, 111 drugs are out of stock in the United States, including the heart disease drug digoxin injection, the chemical drug Dacarbazine and some antibiotics.
The authorities say there are many reasons for the shortage, including production problems, quality problems, drugs and even the suspension of production.
According to the FDA, about 80% of the manufacturers of active pharmaceutical ingredients are located overseas, and the manufacturers have provided the FDA with most of the drug shortage information.
The Administration will also work closely with these manufacturers to address the drug shortage.
【 Omicron variant 】 Study: Omicron carries a cold virus gene or helps avoid the immune system 【 Next 】
Long Island Newspaper Newsday quoted Tom D'Angelo, president of the New York State Association of Pharmacists, as saying the shipping of a large number of medicines, including those for common blood pressure and for the treatment of colds and flu, was blocked.
Because of supply chain problems, the owner of a New York drugstore said there were fewer brands for some drugs, including Ibuprofen.
The National Association of Community Pharmacists (NCPA) released a survey last month that found that most non-chain pharmacies are struggling to fill employee vacancies and cope with supply chain disruptions.
Sixty percent of pharmacies surveyed said they were dealing with supply chain disruptions, and nearly 70 percent said it was difficult to fill staff vacancies.
Stay abreast of the latest development of mutant virus and epidemic vaccine, download the Hong Kong Economic Times App for free now 【 Click here
Editor-in-Chief: Cheng Kam-ling
Follow the latest financial news analysis, like hket Facebook
Subscribe to the Hong Kong Economic Times email newsletter
Receive first-hand financial news Learn more about investment and financial knowledge Submit my consent to receive promotional messages from Hong Kong Economic Times Group. You may also check the privacy policy of this website Terms of Use

The FDA attributed the shortages to production and quality problems.

Title:

Content: US supply chain crisis continues, FDA points to 111 drug shortages
Global Social Hotspot 16: 35 2021 / 12 / 05
Share:
The supply chain crisis in the United States continues, and many goods are facing shortages.
The US media said that the US pharmacies have a number of critical prescription drugs in stock. The US Food and Drug Administration (FDA) pointed out that about 111 drugs are out of stock in the United States. The FDA stressed that it will continue to take measures to monitor the supply chain.
【 Omicron variant 】 Travellers must have a negative test within 48 hours for entering the United Kingdom 【 Next 】
The Federal Reserve warned on Wednesday that large parts of the United States had begun to be affected by supply chain disruptions and labor shortages last month.
According to the FDA website, 111 drugs are out of stock in the United States, including the heart disease drug digoxin injection, the chemical drug Dacarbazine and some antibiotics.
The authorities say there are many reasons for the shortage, including production problems, quality problems, drugs and even the suspension of production.
According to the FDA, about 80% of the manufacturers of active pharmaceutical ingredients are located overseas, and the manufacturers have provided the FDA with most of the drug shortage information.
The Administration will also work closely with these manufacturers to address the drug shortage.
【 Omicron variant 】 Study: Omicron carries a cold virus gene or helps avoid the immune system 【 Next 】
Long Island Newspaper Newsday quoted Tom D'Angelo, president of the New York State Association of Pharmacists, as saying the shipping of a large number of medicines, including those for common blood pressure and for the treatment of colds and flu, was blocked.
Because of supply chain problems, the owner of a New York drugstore said there were fewer brands for some drugs, including Ibuprofen.
The National Association of Community Pharmacists (NCPA) released a survey last month that found that most non-chain pharmacies are struggling to fill employee vacancies and cope with supply chain disruptions.
Sixty percent of pharmacies surveyed said they were dealing with supply chain disruptions, and nearly 70 percent said it was difficult to fill staff vacancies.
Stay abreast of the latest development of mutant virus and epidemic vaccine, download the Hong Kong Economic Times App for free now 【 Click here
Editor-in-Chief: Cheng Kam-ling
Follow the latest financial news analysis, like hket Facebook
Subscribe to the Hong Kong Economic Times email newsletter
Receive first-hand financial news Learn more about investment and financial knowledge Submit my consent to receive promotional messages from Hong Kong Economic Times Group. You may also check the privacy policy of this website Terms of Use

About 80% of active pharmaceutical ingredient manufacturers, mostly overseas, provide the FDA with drug shortage information.

Title:

Content: US supply chain crisis continues, FDA points to 111 drug shortages
Global Social Hotspot 16: 35 2021 / 12 / 05
Share:
The supply chain crisis in the United States continues, and many goods are facing shortages.
The US media said that the US pharmacies have a number of critical prescription drugs in stock. The US Food and Drug Administration (FDA) pointed out that about 111 drugs are out of stock in the United States. The FDA stressed that it will continue to take measures to monitor the supply chain.
【 Omicron variant 】 Travellers must have a negative test within 48 hours for entering the United Kingdom 【 Next 】
The Federal Reserve warned on Wednesday that large parts of the United States had begun to be affected by supply chain disruptions and labor shortages last month.
According to the FDA website, 111 drugs are out of stock in the United States, including the heart disease drug digoxin injection, the chemical drug Dacarbazine and some antibiotics.
The authorities say there are many reasons for the shortage, including production problems, quality problems, drugs and even the suspension of production.
According to the FDA, about 80% of the manufacturers of active pharmaceutical ingredients are located overseas, and the manufacturers have provided the FDA with most of the drug shortage information.
The Administration will also work closely with these manufacturers to address the drug shortage.
【 Omicron variant 】 Study: Omicron carries a cold virus gene or helps avoid the immune system 【 Next 】
Long Island Newspaper Newsday quoted Tom D'Angelo, president of the New York State Association of Pharmacists, as saying the shipping of a large number of medicines, including those for common blood pressure and for the treatment of colds and flu, was blocked.
Because of supply chain problems, the owner of a New York drugstore said there were fewer brands for some drugs, including Ibuprofen.
The National Association of Community Pharmacists (NCPA) released a survey last month that found that most non-chain pharmacies are struggling to fill employee vacancies and cope with supply chain disruptions.
Sixty percent of pharmacies surveyed said they were dealing with supply chain disruptions, and nearly 70 percent said it was difficult to fill staff vacancies.
Stay abreast of the latest development of mutant virus and epidemic vaccine, download the Hong Kong Economic Times App for free now 【 Click here
Editor-in-Chief: Cheng Kam-ling
Follow the latest financial news analysis, like hket Facebook
Subscribe to the Hong Kong Economic Times email newsletter
Receive first-hand financial news Learn more about investment and financial knowledge Submit my consent to receive promotional messages from Hong Kong Economic Times Group. You may also check the privacy policy of this website Terms of Use

The FDA will work with manufacturers to address the shortage.

Title:

Content: US supply chain crisis continues, FDA points to 111 drug shortages
Global Social Hotspot 16: 35 2021 / 12 / 05
Share:
The supply chain crisis in the United States continues, and many goods are facing shortages.
The US media said that the US pharmacies have a number of critical prescription drugs in stock. The US Food and Drug Administration (FDA) pointed out that about 111 drugs are out of stock in the United States. The FDA stressed that it will continue to take measures to monitor the supply chain.
【 Omicron variant 】 Travellers must have a negative test within 48 hours for entering the United Kingdom 【 Next 】
The Federal Reserve warned on Wednesday that large parts of the United States had begun to be affected by supply chain disruptions and labor shortages last month.
According to the FDA website, 111 drugs are out of stock in the United States, including the heart disease drug digoxin injection, the chemical drug Dacarbazine and some antibiotics.
The authorities say there are many reasons for the shortage, including production problems, quality problems, drugs and even the suspension of production.
According to the FDA, about 80% of the manufacturers of active pharmaceutical ingredients are located overseas, and the manufacturers have provided the FDA with most of the drug shortage information.
The Administration will also work closely with these manufacturers to address the drug shortage.
【 Omicron variant 】 Study: Omicron carries a cold virus gene or helps avoid the immune system 【 Next 】
Long Island Newspaper Newsday quoted Tom D'Angelo, president of the New York State Association of Pharmacists, as saying the shipping of a large number of medicines, including those for common blood pressure and for the treatment of colds and flu, was blocked.
Because of supply chain problems, the owner of a New York drugstore said there were fewer brands for some drugs, including Ibuprofen.
The National Association of Community Pharmacists (NCPA) released a survey last month that found that most non-chain pharmacies are struggling to fill employee vacancies and cope with supply chain disruptions.
Sixty percent of pharmacies surveyed said they were dealing with supply chain disruptions, and nearly 70 percent said it was difficult to fill staff vacancies.
Stay abreast of the latest development of mutant virus and epidemic vaccine, download the Hong Kong Economic Times App for free now 【 Click here
Editor-in-Chief: Cheng Kam-ling
Follow the latest financial news analysis, like hket Facebook
Subscribe to the Hong Kong Economic Times email newsletter
Receive first-hand financial news Learn more about investment and financial knowledge Submit my consent to receive promotional messages from Hong Kong Economic Times Group. You may also check the privacy policy of this website Terms of Use

US medicine shortages rose 30% in 2022 from 2021.

Title:

Content: The New York Times Original
Continue reading Growing drug shortage in the United States has become a threat to national security
The shortage of medicines in the United States last year increased compared to 2021 by 30%, according to The New York Times.
However, the article notes that the growing shortage of inexpensive but critical drugs poses a national security threat to the United States.
The growing shortage of inexpensive but critical drugs poses a threat to U.S. national security and forces hospitals to make “terrible ” choices, writes The New York Times, citing a report prepared for hearings in the U.S. Senate.
According to this report, the shortage of medicines last year increased by almost 30% compared to 2021, with an average shortage of medicines observed for 18 months, and for some drugs – 15 years.
Among the drugs in short supply are conventional antibiotics and anesthetics, the article said.
Senator Gary Peters, a Democrat from Michigan and chairman of the Senate Committee on Homeland Security and Government Affairs, said that these problems are related to economic factors, an opaque supply chain and the fact that 80% to 90% of some products are made abroad.
“Taken together, these underlying causes not only raise serious concerns about ensuring proper patient care, but also pose a serious threat to national security, ” Peters said.
Dr. Andrew Schumann, an oncology surgeon from Michigan, told senators at the hearing that the shortage of drugs in his field is "a tragedy occurring in slow motion."
As Schumann noted, recently due to the shortage of one cheap, but well-proven cancer drug, he had to choose which patients will receive this drug.
The article notes that many of the cheapest drugs tend to be made in countries such as India and China, where they are inexpensive to manufacture.
However, this concentration of production capacity creates an additional level of vulnerability to problems such as natural disasters and political unrest, emphasizes The New York Times.
The materials of InoTV contain estimates of exclusively foreign media and do not reflect the position of RT
We publish on Twitter relevant foreign articles selected by the editorial office of InoTV
source
New York Times United States of America
tags
disease india china medicine usa
Today in the media
Popular
INFOX.SG
RT News Feed
Partners news

Medicine shortages typically last 18 months, but can persist for up to 15 years.

Title:

Content: The New York Times Original
Continue reading Growing drug shortage in the United States has become a threat to national security
The shortage of medicines in the United States last year increased compared to 2021 by 30%, according to The New York Times.
However, the article notes that the growing shortage of inexpensive but critical drugs poses a national security threat to the United States.
The growing shortage of inexpensive but critical drugs poses a threat to U.S. national security and forces hospitals to make “terrible ” choices, writes The New York Times, citing a report prepared for hearings in the U.S. Senate.
According to this report, the shortage of medicines last year increased by almost 30% compared to 2021, with an average shortage of medicines observed for 18 months, and for some drugs – 15 years.
Among the drugs in short supply are conventional antibiotics and anesthetics, the article said.
Senator Gary Peters, a Democrat from Michigan and chairman of the Senate Committee on Homeland Security and Government Affairs, said that these problems are related to economic factors, an opaque supply chain and the fact that 80% to 90% of some products are made abroad.
“Taken together, these underlying causes not only raise serious concerns about ensuring proper patient care, but also pose a serious threat to national security, ” Peters said.
Dr. Andrew Schumann, an oncology surgeon from Michigan, told senators at the hearing that the shortage of drugs in his field is "a tragedy occurring in slow motion."
As Schumann noted, recently due to the shortage of one cheap, but well-proven cancer drug, he had to choose which patients will receive this drug.
The article notes that many of the cheapest drugs tend to be made in countries such as India and China, where they are inexpensive to manufacture.
However, this concentration of production capacity creates an additional level of vulnerability to problems such as natural disasters and political unrest, emphasizes The New York Times.
The materials of InoTV contain estimates of exclusively foreign media and do not reflect the position of RT
We publish on Twitter relevant foreign articles selected by the editorial office of InoTV
source
New York Times United States of America
tags
disease india china medicine usa
Today in the media
Popular
INFOX.SG
RT News Feed
Partners news

Drugs like antibiotics and anesthetics are in short supply.

Title:

Content: The New York Times Original
Continue reading Growing drug shortage in the United States has become a threat to national security
The shortage of medicines in the United States last year increased compared to 2021 by 30%, according to The New York Times.
However, the article notes that the growing shortage of inexpensive but critical drugs poses a national security threat to the United States.
The growing shortage of inexpensive but critical drugs poses a threat to U.S. national security and forces hospitals to make “terrible ” choices, writes The New York Times, citing a report prepared for hearings in the U.S. Senate.
According to this report, the shortage of medicines last year increased by almost 30% compared to 2021, with an average shortage of medicines observed for 18 months, and for some drugs – 15 years.
Among the drugs in short supply are conventional antibiotics and anesthetics, the article said.
Senator Gary Peters, a Democrat from Michigan and chairman of the Senate Committee on Homeland Security and Government Affairs, said that these problems are related to economic factors, an opaque supply chain and the fact that 80% to 90% of some products are made abroad.
“Taken together, these underlying causes not only raise serious concerns about ensuring proper patient care, but also pose a serious threat to national security, ” Peters said.
Dr. Andrew Schumann, an oncology surgeon from Michigan, told senators at the hearing that the shortage of drugs in his field is "a tragedy occurring in slow motion."
As Schumann noted, recently due to the shortage of one cheap, but well-proven cancer drug, he had to choose which patients will receive this drug.
The article notes that many of the cheapest drugs tend to be made in countries such as India and China, where they are inexpensive to manufacture.
However, this concentration of production capacity creates an additional level of vulnerability to problems such as natural disasters and political unrest, emphasizes The New York Times.
The materials of InoTV contain estimates of exclusively foreign media and do not reflect the position of RT
We publish on Twitter relevant foreign articles selected by the editorial office of InoTV
source
New York Times United States of America
tags
disease india china medicine usa
Today in the media
Popular
INFOX.SG
RT News Feed
Partners news

Most medical products are made abroad, contributing to the shortage.

Title:

Content: The New York Times Original
Continue reading Growing drug shortage in the United States has become a threat to national security
The shortage of medicines in the United States last year increased compared to 2021 by 30%, according to The New York Times.
However, the article notes that the growing shortage of inexpensive but critical drugs poses a national security threat to the United States.
The growing shortage of inexpensive but critical drugs poses a threat to U.S. national security and forces hospitals to make “terrible ” choices, writes The New York Times, citing a report prepared for hearings in the U.S. Senate.
According to this report, the shortage of medicines last year increased by almost 30% compared to 2021, with an average shortage of medicines observed for 18 months, and for some drugs – 15 years.
Among the drugs in short supply are conventional antibiotics and anesthetics, the article said.
Senator Gary Peters, a Democrat from Michigan and chairman of the Senate Committee on Homeland Security and Government Affairs, said that these problems are related to economic factors, an opaque supply chain and the fact that 80% to 90% of some products are made abroad.
“Taken together, these underlying causes not only raise serious concerns about ensuring proper patient care, but also pose a serious threat to national security, ” Peters said.
Dr. Andrew Schumann, an oncology surgeon from Michigan, told senators at the hearing that the shortage of drugs in his field is "a tragedy occurring in slow motion."
As Schumann noted, recently due to the shortage of one cheap, but well-proven cancer drug, he had to choose which patients will receive this drug.
The article notes that many of the cheapest drugs tend to be made in countries such as India and China, where they are inexpensive to manufacture.
However, this concentration of production capacity creates an additional level of vulnerability to problems such as natural disasters and political unrest, emphasizes The New York Times.
The materials of InoTV contain estimates of exclusively foreign media and do not reflect the position of RT
We publish on Twitter relevant foreign articles selected by the editorial office of InoTV
source
New York Times United States of America
tags
disease india china medicine usa
Today in the media
Popular
INFOX.SG
RT News Feed
Partners news

Economic factors and supply chain issues cause the medication shortage.

Title:

Content: The New York Times Original
Continue reading Growing drug shortage in the United States has become a threat to national security
The shortage of medicines in the United States last year increased compared to 2021 by 30%, according to The New York Times.
However, the article notes that the growing shortage of inexpensive but critical drugs poses a national security threat to the United States.
The growing shortage of inexpensive but critical drugs poses a threat to U.S. national security and forces hospitals to make “terrible ” choices, writes The New York Times, citing a report prepared for hearings in the U.S. Senate.
According to this report, the shortage of medicines last year increased by almost 30% compared to 2021, with an average shortage of medicines observed for 18 months, and for some drugs – 15 years.
Among the drugs in short supply are conventional antibiotics and anesthetics, the article said.
Senator Gary Peters, a Democrat from Michigan and chairman of the Senate Committee on Homeland Security and Government Affairs, said that these problems are related to economic factors, an opaque supply chain and the fact that 80% to 90% of some products are made abroad.
“Taken together, these underlying causes not only raise serious concerns about ensuring proper patient care, but also pose a serious threat to national security, ” Peters said.
Dr. Andrew Schumann, an oncology surgeon from Michigan, told senators at the hearing that the shortage of drugs in his field is "a tragedy occurring in slow motion."
As Schumann noted, recently due to the shortage of one cheap, but well-proven cancer drug, he had to choose which patients will receive this drug.
The article notes that many of the cheapest drugs tend to be made in countries such as India and China, where they are inexpensive to manufacture.
However, this concentration of production capacity creates an additional level of vulnerability to problems such as natural disasters and political unrest, emphasizes The New York Times.
The materials of InoTV contain estimates of exclusively foreign media and do not reflect the position of RT
We publish on Twitter relevant foreign articles selected by the editorial office of InoTV
source
New York Times United States of America
tags
disease india china medicine usa
Today in the media
Popular
INFOX.SG
RT News Feed
Partners news

Production capacity in countries like India and China creates vulnerability to natural disasters and political unrest.

Title:

Content: The New York Times Original
Continue reading Growing drug shortage in the United States has become a threat to national security
The shortage of medicines in the United States last year increased compared to 2021 by 30%, according to The New York Times.
However, the article notes that the growing shortage of inexpensive but critical drugs poses a national security threat to the United States.
The growing shortage of inexpensive but critical drugs poses a threat to U.S. national security and forces hospitals to make “terrible ” choices, writes The New York Times, citing a report prepared for hearings in the U.S. Senate.
According to this report, the shortage of medicines last year increased by almost 30% compared to 2021, with an average shortage of medicines observed for 18 months, and for some drugs – 15 years.
Among the drugs in short supply are conventional antibiotics and anesthetics, the article said.
Senator Gary Peters, a Democrat from Michigan and chairman of the Senate Committee on Homeland Security and Government Affairs, said that these problems are related to economic factors, an opaque supply chain and the fact that 80% to 90% of some products are made abroad.
“Taken together, these underlying causes not only raise serious concerns about ensuring proper patient care, but also pose a serious threat to national security, ” Peters said.
Dr. Andrew Schumann, an oncology surgeon from Michigan, told senators at the hearing that the shortage of drugs in his field is "a tragedy occurring in slow motion."
As Schumann noted, recently due to the shortage of one cheap, but well-proven cancer drug, he had to choose which patients will receive this drug.
The article notes that many of the cheapest drugs tend to be made in countries such as India and China, where they are inexpensive to manufacture.
However, this concentration of production capacity creates an additional level of vulnerability to problems such as natural disasters and political unrest, emphasizes The New York Times.
The materials of InoTV contain estimates of exclusively foreign media and do not reflect the position of RT
We publish on Twitter relevant foreign articles selected by the editorial office of InoTV
source
New York Times United States of America
tags
disease india china medicine usa
Today in the media
Popular
INFOX.SG
RT News Feed
Partners news

A shortage of critical drugs threatens U.S. national security.

Title:

Content: The New York Times Original
Continue reading Growing drug shortage in the United States has become a threat to national security
The shortage of medicines in the United States last year increased compared to 2021 by 30%, according to The New York Times.
However, the article notes that the growing shortage of inexpensive but critical drugs poses a national security threat to the United States.
The growing shortage of inexpensive but critical drugs poses a threat to U.S. national security and forces hospitals to make “terrible ” choices, writes The New York Times, citing a report prepared for hearings in the U.S. Senate.
According to this report, the shortage of medicines last year increased by almost 30% compared to 2021, with an average shortage of medicines observed for 18 months, and for some drugs – 15 years.
Among the drugs in short supply are conventional antibiotics and anesthetics, the article said.
Senator Gary Peters, a Democrat from Michigan and chairman of the Senate Committee on Homeland Security and Government Affairs, said that these problems are related to economic factors, an opaque supply chain and the fact that 80% to 90% of some products are made abroad.
“Taken together, these underlying causes not only raise serious concerns about ensuring proper patient care, but also pose a serious threat to national security, ” Peters said.
Dr. Andrew Schumann, an oncology surgeon from Michigan, told senators at the hearing that the shortage of drugs in his field is "a tragedy occurring in slow motion."
As Schumann noted, recently due to the shortage of one cheap, but well-proven cancer drug, he had to choose which patients will receive this drug.
The article notes that many of the cheapest drugs tend to be made in countries such as India and China, where they are inexpensive to manufacture.
However, this concentration of production capacity creates an additional level of vulnerability to problems such as natural disasters and political unrest, emphasizes The New York Times.
The materials of InoTV contain estimates of exclusively foreign media and do not reflect the position of RT
We publish on Twitter relevant foreign articles selected by the editorial office of InoTV
source
New York Times United States of America
tags
disease india china medicine usa
Today in the media
Popular
INFOX.SG
RT News Feed
Partners news